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ABSTRACT……...

MOLECULAR MECHANISMS OF MANGANESE PORPHYRIN COMPOUNDS IN THE
PREVENTION OF RADIATION-INDUCED FIBROSIS
Radiation therapy is frequently used as a treatment strategy for prostate cancer patients,
which leads to several side effects due to damage to health tissue around the tumor and
the development of radiation-induced fibrosis (RIF). Manganese (III) meso-tetrakis (Nethylpyridinium-2-yl) porphyrin (MnTE-2-PyP or T2E or BMX-010) and other similar
manganese porphyrin compounds that scavenge superoxide molecules have been
demonstrated to be effective radioprotectors and prevent the development of RIF.
However, understanding of the radioprotective molecular pathway associated with these
compounds remains limited. Recent RNA-sequencing data from our laboratory revealed
that MnTE-2-PyP treatment may activate the nuclear factor erythroid 2-related factor 2
(NRF2) signaling pathway. Therefore, we hypothesize that MnTE-2-PyP protects the
prostate from RIF by activating the NRF2 signaling pathway. We identified that MnTE-2PyP is a post-translational activator of NRF2 signaling in prostate fibroblast cells, which
plays a major role in fibroblast activation and myofibroblast differentiation. The mechanism
of NRF2 activation involves an increase in hydrogen peroxide and a corresponding
decrease in kelch-like ECH-associated protein 1 (KEAP1) levels. Further, we identified
some of the key downstream effects of NRF2 pathway activation by MnTE-2-PyP
treatment in prostate fibroblast cells. The downstream changes identified include an
increase in expression of NAD(P)H dehydrogenase [quinone] 1 (NQO1), increase in
nicotinamide adenine dinucleotide (NAD+) levels, increase in sirtuin activity (nuclear and
mitochondrial), and increase in superoxide dismutase 2 (SOD2) expression/activity.
An increase in mitochondrial sirtuin activity correlates with a decrease in SOD2 (K122)
acetylation. This decrease in SOD2 K122 acetylation correlates with an increase in SOD2
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activity and mitochondrial superoxide scavenging capacity. Further, we identified changes
in the consumption of mitochondrial substrates after radiation exposure that may correlate
with mitochondrial health and protection mediated by MnTE-2-PyP. In the context of
radiation exposure, MnTE-2-PyP fails to prevent fibroblast to myofibroblast transformation
in the absence of NRF2 signaling. Collectively, our results indicate that the activation of
the NRF2 signaling pathway by MnTE-2-PyP contributes to radioprotection in prostate
fibroblast cells.

vi
TABLE OF CONTENTS

ACKNOWLEDGEMENTS ................................................................................................ ii
ABSTRACT……... .......................................................................................................... iv
TABLE OF CONTENTS ................................................................................................. vi
LIST OF ABBREVIATIONS ............................................................................................ xi
LIST OF TABLES ........................................................................................................ xvii
LIST OF FIGURES ......................................................................................................xviii
Chapter 1.

Introduction ............................................................................................. 1

1.1.

Radiation exposure .............................................................................................. 1

1.2.

Radiation therapy for prostate cancer treatment ................................................... 2

1.3.

Radiation-induced fibrosis (RIF) ........................................................................... 4

1.4.

ROS drives the development of RIF ..................................................................... 6

1.5.

Antioxidants and antifibrotic agents used to prevent radiation-induced damage
and fibrosis .......................................................................................................10

1.6.

Role of superoxide removal by superoxide dismutase and manganese porphyrin
compounds in preventing RIF ...........................................................................17

1.7.

Signaling pathways altered by manganese porphyrin compounds .......................23

1.8.

The role of the NRF2 signaling pathway in radioprotection ..................................24

Chapter 2.

Materials and methods...........................................................................30

2.1.

Cell lines and tissue culture .................................................................................30

2.2.

Real-time quantitative PCR (RT-qPCR) ...............................................................31

2.3.

Collagen contraction assay .................................................................................33

2.4.

Western blotting ..................................................................................................33

vii
2.5.

Gene silencing ....................................................................................................34

2.6.

NAD+/NADH assay ..............................................................................................34

2.7.

Sirtuin activity assay ............................................................................................35

2.8.

Dihydroethidium (DHE) assay .............................................................................35

2.9.

NRF2 enzyme-linked immunosorbent (ELISA) assay ..........................................36

2.10. NRF2 Electrophoretic mobility shift assay (EMSA) ..............................................36
2.11. ROS-GLO H2O2 assay.........................................................................................37
2.12. SOD2 in-gel activity assay ...................................................................................37
2.13. Xanthine oxidase - SOD activity assay ................................................................37
2.14. Cell size analysis .................................................................................................38
2.15. RNA sequencing (RNA-Seq) ...............................................................................38
2.16. Mitochondrial function assays with MitoPlates S-1 ..............................................39
2.17. Oxidative stress TF activation profiling plate array...............................................39
2.18. Statistical analysis ...............................................................................................40
Chapter 3.
3.1.

Results ....................................................................................................41

MnTE-2-PyP treatment and radiation exposure-mediated changes in gene
expression ........................................................................................................41

3.2.

MnTE-2-PyP treatment and radiation exposure-mediated changes in extracellular
matrix gene expression ....................................................................................45

3.3.

MnTE-2-PyP treatment and radiation exposure mediated changes in gene
expression in mouse primary prostate fibroblast cells .......................................49

3.4.

MnTE-2-PyP treatment and radiation exposure mediated changes COL3A1
protein levels in human prostate fibroblast cells ................................................52

viii
3.5.

MnTE-2-PyP treatment and radiation exposure mediated changes in NRF2
signaling pathway downstream targets in RNA-seq data ..................................55

3.6.

MnTE-2-PyP treatment and radiation exposure mediated changes in levels of the
NRF2 signaling pathway of prostate fibroblast cells ..........................................58

3.7.

MnTE-2-PyP treatment dose required for NRF2 pathway activation ....................61

3.8.

MnTE-2-PyP treatment time course analysis of NRF2 levels in the nucleus of
prostate fibroblast cells .....................................................................................64

3.9.

MnTE-2-PyP treatment increases NRF2’s DNA binding activity ..........................67

3.10. Nuclear extracts of prostate fibroblast have increased NRF2-DNA interaction upon
MnTE-2-PyP treatment .....................................................................................70
3.11. Time course analysis of NQO1 and NRF2 mRNA levels after MnTE-2-PyP
treatment ..........................................................................................................73
3.12. MnTE-2-PyP mediated reduction in KEAP1 levels (canonical) precedes changes
in SQSTM1 (non-canonical) .............................................................................76
3.13. Changes in SQSTM1 occurs after NRF2 pathway activation by MnTE-2-PyP .....79
3.14. MnTE-2-PyP treatment does not activate NRF2 signaling in KEAP1 knockout
mouse embryonic fibroblast cells ......................................................................82
3.15. MnTE-2-PyP treatment leads to an increase in hydrogen peroxide levels ...........85
3.16. Hydrogen peroxide treatment activates the NRF2 signaling pathway ..................88
3.17. Removal of hydrogen peroxide using N-acetyl cysteine (NAC) treatment prevents
NRF2 pathway activation by MnTE-2-PyP treatment ........................................91
3.18. MnTE-2-PyP treatment increased NAD+ and NADH levels ..................................94
3.19. MnTE-2-PyP treatment increased the activity of sirtuin family proteins in nuclear
and mitochondrial extracts ................................................................................97

ix
3.20. MnTE-2-PyP treatment increased SOD2 levels, SOD2 deacetylation (Ac-K122)
and SOD2 activity ...........................................................................................100
3.21. NRF2 downregulation increases α-SMA levels (myofibroblast marker) which is
partially rescued by MnTE-2-PyP treatment ...................................................104
3.22. NRF2 downregulation increases cell size, which is rescued by MnTE-2-PyP
treatment due to partial NRF2 activation.........................................................108
3.23. NRF2 downregulation activates fibroblast cells, which is rescued by MnTE-2-PyP
treatment due to partial NRF2 activation.........................................................111
3.24. NRF2 downregulation increases superoxide and total ROS levels, and MnTE-2PyP treatment reduces superoxide and total ROS levels in HPrF cells ...........114
3.25. MnTE-2-PyP cannot prevent an increase in the α-SMA levels post-irradiation in
the absence of the NRF2 pathway..................................................................117
3.26. MnTE-2-PyP treatment cannot prevent myofibroblast formation post-irradiation in
the absence of the NRF2 pathway..................................................................120
3.27. Prostate fibroblasts from NRF2-/- mice do not undergo transformation to
myofibroblasts post-irradiation ........................................................................123
3.28. Mitochondrial function assayed by measuring the flow of electrons into the
electron transport chain, post-irradiation, and MnTE-2-PyP treatment ............126
3.29. Time dependent, MnTE-2-PyP mediated activation of 16 oxidative stress related
transcription factors ........................................................................................133
3.30. Time dependent, radiation mediated activation of 16 oxidative stress related
transcription factors ........................................................................................136
3.31. MnTE-2-PyP treatment and radiation exposure mediated changes in NQO1
mRNA in PC3 cells .........................................................................................139
3.32. MnTnBuOE-2-PyP (MnTE-2-PyP analog) also activates NRF2 signaling ..........142

x
Chapter 4.

Conclusion and discussion .................................................................145

4.1.

Significance of the NRF2 pathway activation in maintaining human health…. ...145

4.2.

Mechanism of NRF2 pathway activation by manganese porphyrin compounds .148

4.3.

The mechanism by which MnTE-2-PyP prevents myofibroblast formation .........149

4.4.

Reduction of POSTN and COL3A1 in fibroblasts by MnTE-2-PyP .....................154

4.5.

Applications of manganese porphyrin compounds as NRF2 activators in other
disorders and diseases...................................................................................155

4.6.

Mechanisms associated with antitumor and radiosensitizing effects of manganese
porphyrin compounds .....................................................................................158

4.7.

Future directions................................................................................................159

Appendix. ...................................................................................................................165
References .................................................................................................................171

xi
LIST OF ABBREVIATIONS

FOLFIRINOX Folinic acid, fluorouracil, irinotecan, and oxaliplatin
AFC

7-Amino-4-trifluoromethylcoumarin

AP1

Activator protein 1

ARE

Antioxidant response element

ATF4

Activating transcription factor 4

BACH1

BTB domain and CNC homolog 1

BuOE

MnTnBuOE-2-PyP

CAFs

Cancer-associated fibroblasts

CAT

Catalase

CBF/NFY

Nuclear transcription factor Y

COL1A2

Collagen type I alpha 2 chain

COL3A1

Collagen type III alpha 1 chain

COL5A1

Collagen type V alpha 1 chain

COL6A2

Collagen type VI alpha 2 chain

ddH2O

Double-distilled water

DHE

Dihydroethidium

DMEM

Dulbecco's modified eagle medium

DMF

Dimethylfumarate

xii
DNA

Deoxyribonucleic acid

DTAB

Dodecyltrimethylammonium bromide

DTT

Dithiothreitol

ECM

Extracellular matrix

EGR1

Early growth response 1

ELISA

Enzyme-linked immunosorbent assay

EMSA

Electrophoretic mobility shift assay

ERK

Extracellular-signal-regulated kinase

ETC

Electron transport chain

ETS

E-twenty-six

FACS

Fluorescence-activated cell sorting

FAK

Focal adhesion kinase

FBS

Fetal bovine serum

FDA

Food and drug administration

FGF10

Fibroblast growth factor 10

FGF9

Fibroblast growth factor 9

FOXO1

Forkhead box protein O1

GPx

Glutathione peroxidase

GSK-3

Glycogen synthase kinase 3

xiii
GSR

Glutathione-disulfide reductase

GST

Glutathione s-transferase

GSTA4

Glutathione s-transferase alpha 4

HAT

Histone acetyltransferases

HDAC

Histone deacetylase

HIF

Hypoxia-inducible factors

HO-1

Heme Oxygenase-1

HPrF

Human primary prostate fibroblast

HRP

Horseradish peroxidase

HSF

Heat shock factor

IFN-γ

Interferon gamma

IL-6

Interleukin 6

IRF

Interferon regulatory factor

IκBα

Inhibitor of kappa B

K.O.

Knockout

KEAP1

Kelch like ECH associated protein 1

LAP

Latency-associated peptide

MafK

MAF BZIP transcription factor K

MCP-1

Monocyte chemoattractant protein-1

xiv
MnTE-2-PyP

Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin

MPF

Mouse primary prostate fibroblast

NAC

N-acetyl cysteine

NAD+

Nicotinamide adenine dinucleotide (oxidized)

NADH

Nicotinamide adenine dinucleotide (reduced)

NBT

Nitro blue tetrazolium
Neural precursor cell expressed, developmentally down-

NEDD9
regulated 9
NFAT

Nuclear factor of activated T-cells

NFE2L2

Nuclear factor, erythroid 2 like 2

NF-κB

Nuclear factor kappa-light-chain-enhancer of activated B cells

NOX4

NADPH oxidase 4

NOXs

NADPH oxidases

NQO1

NADPH quinone dehydrogenase 1

NRF2

Nuclear factor erythroid 2-related factor 2

NRF2-/-

NRF2 knockout

P3158

Immortalized human prostate fibroblast

P53

Tumor protein p53

PAGE

Polyacrylamide gel electrophoresis

xv
PAI-1

Plasminogen activator inhibitor-1

PBS

Phosphate-buffered saline

PCR

Polymerase chain reaction

PI3K

phosphoinositide 3-kinases

PKC

protein kinase C

POSTN

Periostin

PVDF

Polyvinylidene difluoride

RNA

Ribonucleic acid

RNA-Seq

RNA sequencing

ROS

Reactive oxygen species

RPLPO

Large ribosomal protein

RPMI

Roswell park memorial institute

RT-qPCR

Real-time quantitative PCR

Scr

Scrambled siRNA

SF

Splicing factor

SIRT3

Sirtuin-3

SMAD

Small mothers against decapentaplegic

SOD

Superoxide dismutase

SOD2

Superoxide dismutase 2

xvi
SQSTM1

Sequestosome 1

SRF

Serum response factor

STAT3

Signal transducer and activator of transcription 3

T2E

MnTE-2-PyP

TBE

Tris base, boric acid, EDTA

TBST

Tris buffered saline with tween 20

TEMED

Tetramethylethylenediamine

TFs

Transcription factors

TGF-β

Transforming growth factor beta

TNF-α

Tumour necrosis factor alpha

TRX

Thioredoxin

TSA

Trichostatin A

W.T.

Wild type

α-SMA

α-Smooth muscle actin

xvii
LIST OF TABLES

Table 1. List of primers used for RT-qPCR.
Table 2. Antioxidants and antifibrotic agents used to prevent radiation-induced damage
and fibrosis.
Table 3. MnTE-2-PyP treatment and radiation exposure mediated changes in NRF2
signaling pathway downstream targets in RNA-Seq data.

xviii
LIST OF FIGURES

Figure 1. ROS drives the development of RIF.
Figure 2. Structure of manganese porphyrin compounds used to remove superoxide and
prevent the development of RIF.
Figure 3. NRF2 and KEAP1 binding partners and domain functions.
Figure 4. MnTE-2-PyP treatment and radiation exposure mediated changes in gene
expression.
Figure 5. MnTE-2-PyP treatment and radiation exposure mediated changes in
extracellular matrix gene expression.
Figure 6. MnTE-2-PyP treatment and radiation exposure mediated changes in gene
expression in mouse primary prostate fibroblast cells.
Figure 7. MnTE-2-PyP treatment and radiation exposure mediated changes COL3A1
protein levels in human prostate fibroblast cells.
Figure 8. MnTE-2-PyP treatment and radiation exposure mediated changes in levels of
NRF2 signaling pathway of prostate fibroblast cells.
Figure 9. MnTE-2-PyP treatment dose required for NRF2 pathway activation.
Figure 10. MnTE-2-PyP treatment time course analysis of NRF2 levels in the nucleus of
prostate fibroblast cells.
Figure 11. MnTE-2-PyP treatment increases NRF2’s DNA binding activity.
Figure 12. Nuclear extracts of prostate fibroblast have increased NRF2-DNA interaction
upon MnTE-2-PyP treatment.

xix
Figure 13. Time course analysis of NQO1 and NRF2 mRNA levels after MnTE-2-PyP
treatment.
Figure 14. MnTE-2-PyP mediated reduction in KEAP1 levels (canonical) precedes
changes in SQSTM1 (non-canonical).
Figure 15. Changes in SQSTM1 occurs after NRF2 pathway activation by MnTE-2-PyP.
Figure 16. MnTE-2-PyP treatment does not activate NRF2 signaling in KEAP1 knockout
mouse embryonic fibroblast cells.
Figure 17. MnTE-2-PyP treatment leads to an increase in hydrogen peroxide levels.
Figure 18. Hydrogen peroxide treatment activates the NRF2 signaling pathway.
Figure 19. Removal of hydrogen peroxide using N-acetyl cysteine (NAC) treatment
prevents NRF2 pathway activation by MnTE-2-PyP treatment.
Figure 20. MnTE-2-PyP treatment increased NAD+ and NADH levels.
Figure 21. MnTE-2-PyP treatment increased the activity of sirtuin family proteins in
nuclear and mitochondrial extracts.
Figure 22. MnTE-2-PyP treatment increased SOD2 levels, SOD2 deacetylation (AcK122) and SOD2 activity.
Figure 23. NRF2 downregulation increases α-SMA levels (myofibroblast marker) which
is partially rescued by MnTE-2-PyP treatment.
Figure 24. NRF2 downregulation increases cell size, which is rescued by MnTE-2-PyP
treatment due to partial NRF2 activation.
Figure 25. NRF2 downregulation activates fibroblast cells, which is rescued by MnTE-2PyP treatment due to partial NRF2 activation.

xx
Figure 26. NRF2 downregulation increases superoxide and total ROS levels, and MnTE2-PyP treatment reduces superoxide and total ROS levels in HPrF cells.
Figure 27. MnTE-2-PyP cannot prevent the increase in α-SMA levels post-irradiation in
the absence of NRF2 pathway.
Figure 28. MnTE-2-PyP treatment cannot prevent myofibroblast formation postirradiation in the absence of NRF2 pathway.
Figure 29. Prostate fibroblasts from NRF2-/- mice do not undergo transformation to
myofibroblasts post-irradiation.
Figure 30. Mitochondrial function assayed by measuring the flow of electrons into the
electron transport chain, post-radiation and MnTE-2-PyP treatment.
Figure 31. Time dependent, MnTE-2-PyP mediated activation of 16 oxidative stress
related transcription factors.
Figure 32. Time dependent, radiation mediated activation of 16 oxidative stress related
transcription factors.
Figure 33. MnTE-2-PyP treatment and radiation exposure mediated changes in NQO1
mRNA in PC3 cells.
Figure 34. MnTnBuOE-2-PyP (MnTE-2-PyP analog) also activates NRF2 signaling.
Figure 35. The mechanism by which MnTE-2-PyP prevents myofibroblast formation.
Figure 36. Role of NRF2 pathway activation by MnTE-2-PyP in radioprotection.
Figure 37. NRF2 pathway activation, in mice treated with MnTE-2-PyP for two months.
Figure 38. NRF2 pathway activation, in mice treated with MnTE-2-PyP for two weeks.

1

Chapter 1.

1.1.

Introduction

Radiation exposure

In physics, radiation is referred to any physical particle or wave that carries energy through
space. Radiation waves are periodic variations of the electric and magnetic field intensity.
Radiation waves can be classified into either high energy waves that have a low
wavelength or low energy waves that have a high wavelength. Low energy – high
wavelength radiation includes radiowaves, microwaves, infrared, and visible light. High
energy – low wavelength radiation, which is also referred to as ionizing radiation includes
ultraviolet, X-rays, and gamma-rays. Ionizing radiation has high tissue penetration power
and is known to damage molecules in living systems by detaching electrons from atoms
or molecules within a short span of exposure [2].
Life on Earth is continuously exposed to different kinds of radiation, and life has evolved
in the presence of radiation. The duration, intensity (distance from the source), and type
of radiation exposure can have a distinct effect on human health [3]. In medicine, ionizing
radiation is used in cancer radiation therapy, dental care, nuclear medicine, and imaging
for diagnosis. Further, humans can be exposed to higher than basal amounts of ionizing
radiation during a nuclear explosion, air travel, mining of radioactive material, handling of
nuclear power plant fuel, radioactive research laboratories, or space exploration [2].
Depending on the duration and intensity of ionizing radiation exposure, the human body
can sometimes tolerate and repair itself from the damage caused by ionizing radiation.
However, in situations where the body cannot tolerate or repair itself, therapeutic
intervention is needed to prevent the damage caused to normal tissue and cancer
formation due to radiation exposure [4].
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In cancer radiation therapy, ionizing radiation (X-rays or γ-irradiation) is used to damage
tumor cells and cause cell death. In the case of X-rays or γ-irradiation, ~70% of photons
traversing a cell interact with water molecules that causes water radiolysis [5-7]. Radiation
damage is then mediated through the displacement of electrons from atoms and
molecules. Water lysis is followed by the formation of free radical species (unpaired
electrons), reactive oxygen species (ROS) and reactive nitrogen species (RNS) that
interact, damage or interfere with the normal functioning of macromolecules (DNA, lipids
and proteins) [4]. The reactive molecules formed include hydroxyl radicals (•OH),
hydroperoxy radicals (HOO•), hydrogen peroxide (H2O2), superoxide (O2•−) and
peroxynitrite (ONOO−) [8]. An acute increase in ROS post-irradiation can also trigger a
cycle of higher ROS generation through an increase in levels and activity of several
prooxidant enzymes, such as NADPH oxidases (NOXs), cyclooxygenases (COXs), nitric
oxide synthases (NOSs), and lipoxygenases (LOXs) [9]. This further contributes to tumor
cell death or stalling in tumor growth. An unintended consequence of the damage caused
to tumor cells by radiation therapy is the damage caused to normal tissue surrounding the
tumor.

1.2.

Radiation therapy for prostate cancer treatment

It is estimated that there was 174,650 new prostate cancer cases diagnosed in 2019 in
the US [10]. About 109.5 per 100,000 men per year are diagnosed with prostate cancer
based on 2012-2016 statistics. Further, in 2016, there were an estimated 3,110,403 men
living with prostate cancer in the United States [11]. It is the second most diagnosed
cancer and the second leading cause of cancer death in men in the United States [10].
The prostate is a part of the male reproductive system that functions to provide alkaline
prostate fluid that comprises approximately 70% of the seminal volume (semen) [12]. The
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secretions provide lubrication and nutrition for the sperm. Semen is forced into the urethra
by contraction of the prostate muscles during ejaculation [13, 14]. The prostate is located
directly below the bladder and above the muscles of the pelvic floor [13-15]. It is in close
vicinity to the rectum, seminal vesicles and seminal ducts, bladder, pelvic bone, prostatic
plexus (nervous), and pudendal nerve [16]. The prostate gland is also surrounded by a
capsule of connective tissue containing many smooth muscle fibers and elastic connective
tissue, which makes it elastic in nature [17]. Therefore, it is essential to prevent damage
to the prostate and the surrounding tissue after radiation therapy for prostate cancer
patients.
Depending on the stage of prostate cancer and other factors, radiation therapy might be
used: as the first treatment without prostatectomy, as a part of hormone therapy, and as
an adjuvant therapy to prostatectomy [18]. It is estimated that nearly half of all prostate
cancer patients will undergo radiation therapy [19]. The current radiation treatment
options, although effective, pose severe side effects that impact the quality of life of
patients. Side effects of radiation therapy for prostate cancer include sexual dysfunction,
genitourinary side-effects, bowel, and rectal wall damage, urinary urgency and frequency,
urethral stricture, and incontinence [20-26]. The underlying cause for the development of
these side-effects is due to the formation of fibrotic tissue [27-31]. Often, this fibrotic tissue
remains unresolved and leads to a dysfunctional organ; this condition is known as
radiation-induced fibrosis (RIF). To minimize the rectal injury to men undergoing radiation
therapy, SpaceOAR hydrogel is used to provide space between the rectum and the
prostate [32, 33]. This separation helps reduce the volume of normal tissue exposed to
radiation and lowers rectal damage. However, other tissues are still susceptible to
radiation damage and therapeutic interventions are still required to prevent sexual
dysfunction and urinary tract side effects.
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Nearly 50% of prostate cancer patients undergo radiation therapy as a treatment strategy
and there are no FDA-approved drugs to either protect the surrounding tissues of the
prostate or prevent the side-effects of radiation therapy. However, there are ongoing
clinical trials for radioprotector drugs for other cancers, which can potentially be used for
prostate cancer radiation therapy clinical trials.
Radioprotectors are compounds that are designed to reduce the damage in normal tissues
caused by radiation [4]. A good radioprotector protects normal cells without changing the
tumor cell sensitivity to radiation damage. Amifostine, which generates a cytoprotective
thiol metabolite in vivo, is an FDA-approved radioprotectant. It has also been carried by
US astronauts on lunar missions as a radioprotector [34, 35]. However, its efficacy as a
radioprotector has been heterogeneous and its use has led to development of several
side-effects [36]. Some of the reported adverse side-effects of amifostine include nausea,
vomiting, hypotension, hypocalcemia, diarrhea, sneezing, somnolence, hiccoughs and
allergic reactions [36, 37]. Therefore, amifostine as a radioprotector has largely fallen out
of use [36].

1.3.

Radiation-induced fibrosis (RIF)

As mentioned, radiation therapy effectively kills tumor cells through ROS generation, and
can also damage nearby healthy tissues [9]. This results in the development of severe
side-effects of radiation therapy and the formation of fibrotic tissue, which reduces patient
quality of life. An increase in ROS after radiation exposure is a known driver for the
development of fibrosis [38]. Fibrosis is characterized by an aberrant accumulation of
extracellular matrix (ECM) proteins that result in the loss of normal tissue and organ
function [39]. It is a signiﬁcant cause of morbidity and mortality worldwide [25, 40-46].
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The major cell type involved in developing ﬁbrosis is the myoﬁbroblast, which primarily
arises from ﬁbroblasts upon radiation exposure. Myoﬁbroblasts can also arise from other
cell types through the process of diﬀerentiation or by epithelial/endothelial-mesenchymal
transitions [47, 48]. These differentiated fibroblasts have a phenotype that is closer to the
smooth muscle cell and can be detected by measuring the expression of myofibroblast
markers such as α-smooth muscle actin (α-SMA), paladin, desmin, and vimentin [49].
Every tissue has a balance between the number of fibroblasts and myofibroblasts that
regulate the tissue functioning through different molecules that are secreted and provide
structural support to surrounding cells by the production of ECM proteins. Further, it is
estimated that myofibroblasts have a >200% increase in cell size and increased protein
synthesis in comparison to normal fibroblasts [50]. The secretory factors produced include
chemokines, cytokines, growth factors and inflammatory mediators that can promote the
development of fibrosis [51].
Under normal conditions, myoﬁbroblasts play a critical role in wound closure after injury
[52, 53]. After wound healing and restoration of ECM to homeostatic levels, these
myoﬁbroblasts undergo apoptosis [48]. However, wounds that fail to heal correctly contain
persistent myoﬁbroblasts that leave a keloidal or hypertrophic scar. These active
myoﬁbroblast cells do not undergo apoptosis after healing and continue to damage the
tissues and organs by producing excessive amounts of ECM proteins. The persistent
nature of an activated myoﬁbroblast is maintained through molecular feedforward loops
by autocrine and paracrine signaling and the inﬂux of inﬂammatory cells [54, 55]. ROS
from other sources, including ROS generating enzymes, and damaged mitochondria, are
also involved in the maintenance of these myofibroblast cells [8]. Further, ROS generated
after radiation exposure can drive epigenetic changes, metabolic changes and alter
cellular signaling [39, 56-59].
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1.4.

ROS drives the development of RIF

As mentioned, ROS generation after radiation exposure is a driver for the development of
RIF. An increase in ROS after radiation can occur through the radiolysis of water,
mitochondrial damage, and an increase in expression of ROS generating enzymes
through the activation of the TGF-β signaling pathway [9, 38, 60]. Thereby, setting up a
vicious cycle of high oxidative stress, which drives epigenetic reprogramming of fibroblast
cells to myofibroblasts (Fig. 1) [39, 61, 62].
The mitochondria are essential cellular organelles involved in regulating ROS levels and
cellular metabolism that impacts the formation of myofibroblasts. Under normal metabolic
conditions, the mitochondria produce low basal levels of superoxide via the electron
transport chain, which is required for normal cellular signaling [63]. Ionizing radiation can
directly damage mitochondrial DNA and nuclear DNA that codes for mitochondrial
proteins, which leads to several functional changes in the mitochondrial structure, activity,
and function [64-67]. Similarly, the lipid bilayer of cell membranes can be directly and
indirectly damaged by ionizing radiation leading to apoptosis via an increase in membrane
permeability and disruption of ion gradients [68, 69]. Radiation exposure can result in
excessive production of mitochondrial ROS due to a loss in mitochondrial membrane
integrity/potential or an increase in mitochondrial number [64, 70, 71]. Further, radiationinduced mitochondrial damage reduces the production of tricarboxylic acid (TCA)
metabolites and causes an increase in fatty acid metabolism. The mitochondria also
regulate the generation of epigenetic metabolites such as nicotinamide adenine
dinucleotide (NAD), α-ketoglutarate (α-KG), S-adenosyl methionine (SAM), and acetylCoA [57, 58]. Therefore, damage to the mitochondria by radiation exposure can drive ROS
mediated epigenetic changes leading to the development of RIF (Fig. 1) [39, 72].
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The impact of ROS on TGF-β signaling is the most studied in the context of RIF [68, 73-

75]. An increase in ROS after radiation exposure leads to the activation of the TGF-β
signaling pathway through the oxidation of cysteine residues of the latency-associated
peptide (LAP). Oxidation of LAP leads to a conformational change in LAP, which allows
the release of TGF-β from the latent complex. An active TGF-β, upon binding to TGF-β
receptors, leads to the phosphorylation and activation of transcription factors, such as
SMAD2 and SMAD3 [76]. TGF-β pathway stimulation increases the basal level of ROS
through several NADPH oxidases (NOXs), including NOX4, via the canonical SMAD2/3
signaling factors [77] and activation of PI3K [76, 78]. Generation of ROS through NOX4
upregulation can also lead to the activation of the noncanonical SMAD signaling pathway,
which includes the activation of c-Src and FAK kinases [79]. These changes in the TGFβ signaling pathway and the crosstalk with the PI3K/AKT signaling pathway leads to
changes in the epigenome and the development of ﬁbrosis (Fig. 1) [61, 74].
Regarding genetic changes associated with the development of RIF in prostate tissue.
There has been a study that analyzed the genetic predictors of late radiation-induced
morbidity in prostate cancer patients by Schack, Line MH, et al., in 2017 [29]. In their
research, they identified single nucleotide polymorphism (SNP), rs2682585 minor allele
(A) in the follicle stimulating hormone receptor (FSHR) gene to be involved in resistance
to fibrosis and had the lowest radiation-induced anorectal dysfunction score. In other
tissue types, there are genetic mutations that are related to increased radiosensitivity,
such as mutations in DNA repair pathways (e.g., ATM) and SNPs in TGF-β1.
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Figure 1. ROS drives the development of RIF. Radiation-induced ROS generation
drives fibroblast reprogramming and the development of RIF. ROS can be directly
generated due to radiolysis of water or through the damage of mitochondria. This leads
to the activation of the TGF-β signaling pathway, which sustains an increase in ROS
levels by increasing NOX4 expression, thereby setting up a vicious cycle of high
oxidative stress, which drives epigenetic reprogramming of fibroblast cells to
myofibroblasts. Further, damaged mitochondria have altered production of redoxsensitive epigenetic metabolites that serve as cofactors for chromatin modifying
proteins. NOXs, NADPH oxidases; NAD+, Nicotinamide adenine dinucleotide; SAM, Sadenosylmethionine; α-KG, α-ketoglutarate; ECM, extracellular matrix.
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1.5.

Antioxidants and antifibrotic agents used to prevent radiation-induced

damage and fibrosis

There have been several studies using different antioxidant and anti-fibrotic molecules in
humans and small animal studies to prevent radiation-induced damage or fibrosis (Table
1). The different tissue types studied for RIF include lung, small intestine, thyroid gland,
salivary gland, head and neck tissues, brain, heart, kidney, eye, skin, colon, pelvic tissues
(prostate and ovary), and breast tissues. Some of these studies show radioprotection upon
whole-body radiation exposure, which would be applicable for instances of a nuclear
disaster or fallout. The radiation dose in different studies ranges from a minimum of 2 Gy
to a maximum of 37.5 Gy for small animals. Human beings generally receive a fractionated
dosing scheme which adds up to a total of 20-80 Gy depending on the organ and tissue
sensitivity to radiation damage. Maximum tumor damage and growth inhibition due to
radiation damage is often not achieved due to the restriction in the maximum radiation
dose (>80 Gy) that can be delivered without causing any side effects. Among the different
molecules and agents shown in Table 1, SOD mimics or manganese porphyrin
compounds were able to prevent radiation damage or RIF at a fractionated radiation dose
ranging from 25-30 Gy in small animals. Other molecules such as amifostine, alpha-lipoic
acid, curcumin, NAC, resveratrol and vitamin E generally protected different tissues at a
radiation dose lower than 20 Gy, which again highlights the effectiveness of SOD mimics
or manganese porphyrin compounds in prevention of RIF. Further, some of these
compounds are used at a much higher dose (>10 mg/kg) in comparison to the manganese
porphyrin compounds. Another issue associated with the natural compounds is their poor
bioavailability, which restricts their use in different tissue types.
To treat and prevent RIF, we can either remove the ROS generated after radiation
exposure, inhibit the TGF-β signaling pathway or inhibit the epigenetic alterations (Table
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1). However, inhibiting epigenetic alterations or TGF-β signaling can result in damage to
other normal cells or organs that are not exposed to radiation. Therefore, boosting the
antioxidant capacity of cells before radiation exposure would be the best strategy to
prevent RIF with minimal side effects. Further, antioxidants can prevent activation of the
TGF-β signaling pathway and/or epigenetic modifications observed after radiation
exposure because ROS can drive these other pathways as well.
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Table 1. Antioxidants and antifibrotic agents used to prevent radiation-induced
damage and fibrosis. Column 1, drugs or molecules that have been investigated to
prevent radiation-induced damage and fibrosis. Column 2, tissue of region of body
being exposed to radiation. Column 3, radiation dose used and studied in different
animal models. Column 4, dose and scheme of drug usage. Column 5, cellular pathway
or cellular changes or mechanism studied in the context of radiation damage and
fibrosis. Column 6, respective reference to the study.
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Antioxidant/
Anti-fibrotic
agents

Region

Radiation
Dose /
Animal

Dose

Effects

Refer
ence

AEOL 10150
(Catalytic
SOD mimic)

Lung

28 Gy /
Rats

10-30 mg/kg/day, for
10 weeks

Inhibits TGF-β signaling.

[80]

Small
intestine

15 Gy /
Mice

100 mg/kg, 3 days
before radiation

Reduces inflammation and cell death, and
reduces p-NF-κB, MMP9, and MAPK
signaling. Facilitates regeneration of
vitamin C and E and elevates glutathione
levels [81].

[82]

100 mg/kg, 24 h
before radiation
100 mg/kg, 24 h
before irradiation

Inhibits TGF-β signaling.

[83]

Salivary
gland

18 Gy /
Rats
18 Gy /
Rats

Head and
neck

20–70 Gy
/ Humans

200 mg/m2 to 400
mg/m2

Heart

22.5 Gy /
Rats

Heart

18 Gy /
mice

Kidney

15 Gy

Atorvastatin

Kidney

2 Gy /
mice

CpGoligodeoxyn
ucleotide

Lung

15 Gy /
mice

50 μg CpG-ODN

Lung

18 Gy /
Rats

200 mg/kg/day, 1
week before
radiation

Lung

13.5 Gy /
Mice

1% or 5% (w/w)

Wholebody /
Kidney

5 Gy /
Rats

100 mg/kg/day 1
week before
irradiation by gastric
tube

Inhibits production of proinflammatory
cytokines TNFα, IL-1, IFNγ, and IL-6.

[95]

Lung

10 to 20.5
Gy / Rats

30 mg/kg, 30
minutes before
radiation

Inhibits TGF-β signaling.

[96]

Lung

12 Gy /
Rats

8 mg/kg/day

Reduces oxidative damage, TGF-β and
NF-κB signaling and activated
macrophages.

[97]

Lung

13.5 Gy /
Mice

10% (w/w)

Reduces expression of lung injury
biomarkers (Bax, p21, and TGF-β).
Contains omega-3 fatty acids and lignans
with antioxidant properties.

[98]

35 Gy /
Mice

4 μg, 24 hours
before, 2 days after
radiation, and then
3/week over 6
months

Inhibits TGF-β signaling.

[99]

Alpha-lipoic
acid
Thyroid

Amifostine
(WR-2721)

Curcumin

Erdosteine
Eukarion189
(Catalytic
SODCatalase
mimic)
Eukarion207
(Catalytic
SODCatalase
mimic)
Flaxseed

Follistatin

Hindlimb

160 mg/kg, 15
minutes before
radiation
200 mg/kg, 30
minutes before
radiation
200 mg/kg, 30
minutes before
radiation
50 mg/kg/day for 1
week

Reduces oxidative stress by inhibiting
gp91 mRNA expression.
Thiol compound, free radical scavenger,
reduces oxidative radicals, prevents
xerostomia (dry mouth) post-radiation.

[84]
[85,
86]

Reduces cardiac damage.

[87]

Prevents vasculitis and vascular injury.

[88]

Prevents glomerular and tubular changes
and interstitial fibrotic lesions postradiation.
Reduces the levels of oxidative stress
biomarkers.
Prevents radiation-induced pulmonary
fibrosis by shifting the imbalance of Th1
and Th2 response
Boosts antioxidant defenses by increasing
HO-1. Prevents COX-2 upregulation,
inhibits pro-inflammatory cytokines and
NF-κB signaling.
Prevents radiation-induced pulmonary
fibrosis and reduces LPS-induced TNF-α
production.

[89,
90]
[91]
[92]

[93]

[94]
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GC4401

Wholebody /
Liver

2×2 Gy /
Mice

2 mg/kg before every
fraction

Protects liver in SIRT3−/− animals from
radiation-induced injury.

[100]

GC4419

Oral cavity

60 to 72
Gy /
Human

15 to 112 mg/day,
60 min before
radiation for 3 to 7
weeks

Reduces the frequency and duration of
oral mucositis.

[101]

Genistein
(isoflavone)

Lung

12 Gy /
Rats

50 mg/kg/day

Ginger
extract

Kidney

2,4 and 8
Gy / Rats

50 mg/kg/day for 10
days

Wholebody

8 Gy /
Rats

50 mg/kg/day, 15day pretreatment

Eye

5 Gy /
Rats

40 mg/kg/day, 3
days pretreatment
and up to 7 days
post-radiation

Ginko
Biloba

Reduces oxidative damage, TGF-β and
NF-κB signaling, activated macrophages
and fibrosis.
Alleviates functional and structural
alterations in kidney due to antioxidant
and anti-inflammatory effects.
Attenuates irradiation-induced oxidative
organ injury, by preventing an increase in
LDH and TNF-alpha levels.
Prevents increase in xanthine oxidase
(XO) activity post-radiation.
Corrects the metabolic disturbances
induced in the brain by lowering
dopamine, calcium and zinc contents
while increasing in iron content. Restores
the activities of lactate dehydrogenase
and cholinesterase enzymes.
Reduces TNF‑α, IL‑1β and IL‑6 production
in serum via inhibition of NF‑κB and
downregulates TLR‑4 and HMGB1
expression in the lungs. Reduces ROS
levels and HIF‑1α expression along with
inhibition of NOX‑1 and NOX‑2
expression.
Decreases inflammation, fibrosis, mast
cell and macrophage numbers, and
myocyte necrosis after radiation.

[97]

[102]

[103]

[104]

Wholebody

6 Gy /
Rats

50 and 100
mg/kg/day for 7 days

GTS‑21
(α7-nAChR
agonist)

Lung

12 Gy /
Mice

4 mg/kg/day

Hesperidin

Heart

18 Gy /
Rats

100 mg/kg/day for 7
days

JP4-039
(TEMPOL)

Skin/Leg

35 Gy /
Mice

50uL of formulation,
0.5, 24 and 48h after
radiation

Reduces radiation-induced skin damage.

[108]

KL4
surfactant
(21-amino
acid peptide)

Lung

13.5 Gy /
Mice

120 mg/kg twice
daily

Reduces lung inflammation and oxidative
stress.

[109]

Matrine
(alkaloid)

Wholebody

6-7 Gy /
Rats

Reduces radiation-induced damage by
altering 21 pathways.

[110]

Melatonin

Lung

18 Gy /
Rats

Reduces lipid peroxidation product
malondialdehyde.

[111]

MnTnHex-2PyP
(Catalytic
SOD mimic)

Lung

28 Gy /
Rats

Decreases HIF-1alpha, TGF-β, and VEGF
A expression after radiation.

[112]

Lung

28 Gy /
Rhesus
monkeys

0.05 mg/kg twice
daily for 2 months

Prevents radiation injury in the lungs.

[113]

Prostate

10 Gy /
Mice

6 mg/kg/day, Day 1
to 16

Pelvic
region

20-30 Gy /
Rats

Pelvic
region

37.5 Gy /
Mice

5 mg/kg/week, 1 h
before radiation
10 mg/kg/week, 24 h
before radiation. For
the first two weeks, 3
times/week at a
dose of 5 mg/kg
6 mg/kg/day, 15 min
before radiation
6 mg/kg/day for 10
weeks

MnTE-2-PyP
Or
AEOL 10113
(Catalytic
SOD mimic)

Lung
Lung

28 Gy /
Rats
28 Gy /
Rats

30, 10, 3 mg/kg/day,
3 days before or
after radiation
100 mg/kg once 30
minutes before
radiation
0.05 mg/kg/day for 2
weeks, 2 h postradiation

Inhibits TGF-β signaling. Protects against
decreases in RBC counts, hemoglobin,
and hematocrit.
Ameliorates both acute and chronic
radiation proctitis.

[105]

[106]

[107]

[114]
[115,
116]

Reduces collagen deposition,
inflammation, senescence, fibroblast to
myofibroblast differentiation and
upregulates NQO1 expression.

[117]

Inhibits TGF-β signaling.

[118]

Decreases HIF-1alpha, TGF-β, and VEGF
A expression after radiation.

[119]
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MnTnBuOE2-PyP5
Or
BMX-001
(Catalytic
SOD mimic)

N-acetyl
cysteine
(NAC)

Plasminoge
n activator
inhibitor-1
(PAI-1)
truncated

Brain

5 Gy /
Mice

Brain

8 Gy /
Mice

Colon

2 Gy /
Mice

Wholebody

18 Gy /
Mice

Wholebody

6 Gy /
Rats

1000 mg/kg, 15 min
before radiation

Abdomen

10 Gy /
Rats

300 mg/kg/day

Abdomen

20 Gy /
Mice

300 mg/kg/day, for 7
days

Lung

30 Gy /
Mice

5.4 μg/kg/day for 18
weeks beginning 2
days before
radiation

16 Gy /
Mice
20 Gy /
Mice
60-72 Gy
Humans

300 mg/kg/day for
four weeks
200, 400 mg/kg/day
for 12 weeks
800 mg three
times/day

Lung
Pirfenidone

Intestine
Head and
Neck

1.5 mg/kg, twice
daily, for 14 days
1.6 mg/kg, twice
daily, 24 h before
radiation
0.25 μM every 3
days, for in vitro
studies
500 mg/kg/day, 3
days before and up
to 3 days postradiation

Protects hippocampal neurogenesis.

[120]

Protects the brain from negative effects of
cranial irradiation.

[121,
122]

Prevents activation and increase in cell
size of fibroblast cells from the colon.

[123]

Protects the lung and red blood cells from
glutathione depletion following irradiation.

[124]

Protects rat femoral bone marrow cells
from radiation-induced genotoxicity and
cytotoxicity.
Alleviates the negative effects of
radiotherapy on incisional wound healing
by means of reducing oxidative stress
markers.
Prevents gastrointestinal injury, damage to
bone marrow stromal cells and radiationinduced acute death.
Prevents RIF with increased fibrin
metabolism, enhanced matrix
metalloproteinase-3 expression, and
reduced senescence in type 2
pneumocytes

[125]

[126]

[119]

[127]

[128]
Inhibits TGF-β signaling.
[129]
-

[130]

Podophyllot
oxin and
rutin
combinatio
n
(G-003M)

Lung

11 Gy /
Mice

5 mg/kg once

Reduces radiation-induced oxidative and
inflammatory stress

[131]

Polydatin

Lung

15 Gy /
Mice

100 mg/kg/day

Exerts anti-inflammation and anti-oxidative
properties through Nrf2 signaling and Sirt3
upregulation.

[132]

Intestine

13 Gy /
Mice

Skin-hind
leg

35 Gy and
10 Gy /
Mice

Quercetin

Resveratrol

100 mg/kg/day for 6
days before and
after radiation
Quercetinformulated chow
(1% by weight)

Inhibits TGF-β signaling.

[135]

[136]

[133]

[134]

Intestine

7 Gy /
Mice

40 mg/kg/day, 1-day
pretreatment and up
to day 5

Prevents intestine damage via the
activation of Sirt1. Improves intestinal
morphology, decreases apoptosis of crypt
cells, maintained cell regeneration, and
ameliorated SOD2 expression and activity.
Regulates Sirt1 and acetylated p53
expression that is perturbed by irradiation.

Wholebody

3 Gy /
Mice

100 mg/kg/day, 2
days pretreatment
and up to 30 days

Reduces radiation-induced chromosome
aberration frequencies.

Salivary
gland

15 Gy /
Mice

20 mg/kg/day

Ovary

21 Gy/
Rats

25 mg/kg/day for 2
weeks

Wholebody /
Hematopoi

6 Gy /
Mice

20 mg/kg/day for 7
days before and
then up to 30 days
post-radiation

Inhibits TGF-β signaling. Protects salivary
glands against the negative effects of
irradiation.
Counteracts the effect of radiation and
upregulates the gene expression of
PPAR-γ and SIRT1, leading to inhibition of
NF-κB provoked inflammatory cytokines.
Protects from radiation-induced injury, in
part, via activation of Sirt1.

[137]

[138,
139]

[140]
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etic stem
cell
Skin
Lung
rhNRG-1β

Heart

Silibinin

Breast

SOD–
gliadin

Hind leg /
Skin

Soy
isoflavones

Taurine

35 Gy /
Mice
13 Gy /
Mice
20 Gy /
Rats
46.8-50.4
Gy /
Human
25 Gy /
Mice

Prostate

73.8 to
77.5 Gy /
Humans

Lung

12 Gy /
Mice

Lung

10 Gy

Lung

12 Gy /
Mice

1% by weight

Inhibits TGF-β signaling.

100 mg/kg/day for 7
days
15 μg/kg 3 days
before and 7 days
after radiation

Prevents lung injury by reducing
inflammation and fibrosis.
Prevents fibrosis and preserves cardiac
function via the ErbB2-ERK-SIRT1
signaling pathway.
Vitamin E may be clinically useful in
preventing fibrosis after radiation in highrisk patients.
Reduces dermal thickness and fibrosis
after irradiation.

400 IU for 6 months
10,000 units/kg/day
for 8 days
200 mg tablet
containing (50 mg
soy isoflavones;
genistein:daidzein:gl
ycitein at a ratio of
1.1:1:0.2)
50 mg/kg/day, 3
days before and up
to 4 months after
radiation

[134]
[141]
[142]

[143]
[144]

Reduces the urinary, intestinal, and sexual
adverse effects in patients with prostate
cancer receiving radiation therapy.

[145]

Mitigates inflammatory infiltrates and
radiation-induced lung injury.

[146]

250 mg/kg/day, 3day pretreatment

Inhibits the infiltration and activation of
macrophages and neutrophils induced by
radiation in lungs.

[147]

250 mg/kg/day, 3day pretreatment
and up to 4 months
after radiation

Inhibits the infiltration and activation of
macrophages and neutrophils induced by
radiation in lungs.

[146]

[148]

Lung

14 Gy /
Mice

32 mg/kg/day

Inhibits TGF-β signaling. Taurine essential
amino acid is involved in osmoregulation,
anti-oxidation, detoxification, membrane
stabilization, neuromodulation, cardiac
function and central nervous system
development.

Brain

6 Gy /
Rats

2 oral doses of
500 mg/kg/day for 2
weeks

Taurine has antioxidant, anti-inflammatory,
and anti-apoptotic effects.

[149]

Sperm
cells

8 Gy /
Mice
spermatoc
ytes (GC-2
cells)

40mM

Activates Nrf2/HO-1 signaling.

[150]

Lung &
heart

20 Gy /
Rats

Protects lungs and heart tissues from
radiation-damage.

[151]

Lung

14 Gy /
Rats

Protects against the development of RIF.

[152]

Vitamin E

Wholebody

9.2 Gy /
Mice
22 Gy /
Mice

SKI2162

Hind limb

GV1001

Skin

6 Gy /
Mice

XH-103

Intestine

11 Gy /
Mice

2.5% of diet 2 weeks
before radiation or
150 mg injected 4 h
before radiation
1.1 mg/day
dissolved in 0.1 ml
olive oil injected
50 mg/kg 24 h
before radiation
10 mg/kg/day, 5
times/week
1 mg/kg/day and 5
mg/kg/day for 4
weeks
200 mg/kg, 1 before
radiation

Protects against acute radiation
syndrome.
An inhibitor of the TGF-β type I receptor
(ALK5), inhibits radiation-induced fibrosis.

[153]
[154]

Suppresses TGF-β signaling.

[155]

Prevents damage to the intestinal cryptvillus structure.

[156]
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1.6.

Role of superoxide removal by superoxide dismutase and manganese

porphyrin compounds in preventing RIF

Superoxide (O2•−) is an anionic ROS that contains an extra electron in comparison to
molecular oxygen [157]. Molecular oxygen has two unpaired electrons, whereas
superoxide has one unpaired electron. Superoxide is produced in all cells by the oneelectron reduction of oxygen [158]. This can happen intracellularly either through the
mitochondria or through the normal catalytic function of enzymes such as NADPH
oxidases, xanthine oxidases, and cytochrome P450 family. Environmental factors such as
UV light, cigarette smoke, environmental pollutants, and ionizing radiation exposure are
known to increase superoxide levels [158, 159]. Apart from RIF, excessive amounts of
superoxide generation plays a major role in the development of cancer, atherosclerosis,
rheumatoid arthritis, diabetes, liver damage, and central nervous system disorders [160,
161]. An increase in superoxide levels leads to cellular toxicity and is a strategy used by
immune cells to kill microorganisms in phagocytes [162]. Further, superoxide can react
with nitric oxide, forming peroxynitrite species (ONOO-, ONOOH), these proxynitrite
species can decompose to yield the hydroxyl radical (•OH) and the nitrogen dioxide radical
(•NO2), which are all very reactive and highly oxidizing species [161]. Therefore, levels of
superoxide within cells needs to be tightly controlled and kept at low levels.
To combat superoxide toxicity, all human cells express three superoxide dismutase
(SODs) enzymes. In a two-step reaction, these enzymes convert two molecules of
superoxide into hydrogen peroxide (H2O2) and oxygen [163]. The three enzymes that
perform this reaction are SOD1 (Cu/ZnSOD), SOD2 (MnSOD), and SOD3 (Ec SOD).
SOD1 binds copper and zinc ions and functions as a homodimer that is located in the
cytosol and the intermembrane space of the mitochondria [164]. SOD2, binds one
manganese ion per subunit, is a homotetramer that is located in the mitochondrial matrix.
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SOD3 or Ec-SOD, is a tetrameric protein and is found in the extracellular matrix of tissues.
Loss of SODs is associated with several human pathologies, including pulmonary fibrosis,
cardiovascular and degenerative neurological diseases [165, 166]. Therefore, there has
been a need to develop and test compounds that reduce superoxide levels for different
therapeutic applications in medicine.
Manganese porphyrin compounds are small water-soluble compounds that scavenge
superoxide molecules [167]. It has taken three decades of work to design and synthesize
these compounds that mimic the activity of native SOD enzymes for clinical use [168].
They have a catalytic active site similar to SOD2 (MnSOD) enzyme and catalyze the twostep reaction: (1) MnIIIP5+ + O2•- ⇌ MnIIP4+ + O2, and (2) MnIIP4+ + O2•- + 2H+ ⇌ MnIIIP5+ +
H2O2 [163]. Apart from superoxide scavenging, these compounds are also known to reduce
lipid peroxides, peroxynitrite levels, and catalyze other diverse redox reactions [168].
Therefore, manganese porphyrin compounds are being studied for their application in
diseases involving superoxide and oxidative stress [169].
MnTE-2-PyP5+ (BMX-010), belongs to the category of manganese porphyrin compounds
[167, 170-175]. MnTE-2-PyP, along with its sister molecules, such as, MnTnBuOE-2PyP5+ [120], MnTnHex-2-PyP5+ [176-178] and MnTDE-2-ImP5+ have been shown to be
effective radioprotectors. In our laboratory, we have shown both MnTE-2-PyP and
MnTnBuOE-2-PyP

protect

from

radiation-induced

fibrosis

by

preventing

the

transformation of fibroblasts to myofibroblasts. Further, we have shown that MnTE-2-PyP
reduces chronic fibrosis and inflammation in irradiated normal pelvic tissue [179].
In our laboratory, we use two of the manganese porphyrin compounds; MnTE-2-PyP (Fig.
2: A) and MnTnBuOE-2-PyP (Fig. 2: B) which have similar molecular structures with the
only difference being the lipophilic side chains of MnTnBuOE-2-PyP . The lipophilic side
chains allow for easier diffusion through the lipophilic cell membrane [167]. This reduces

19
the dose required for treatment (0.5 μM) to achieve the same amount of reduction in
superoxide molecules. Currently, MnTnBuOE-2-PyP5+ (BMX-001), is in Phase I/II clinical
trials as a radioprotector of normal tissues in head and neck (NCT02990468),
glioblastomas cancer patients (NCT02655601), anal cancer treatment (NCT0338650),
and brain metastasized cancers (NCT03608020) [180, 181]. Another SOD mimic
compound, GC4419, has been shown to be an effective radioprotector and is in clinical
trials (NCT02508389, NCT01921426, and NCT03689712) [182, 183]. In addition to
radioprotection, these manganese porphyrin compounds have been reported to have antitumor effects.
Manganese porphyrin compounds do not protect cancer cells and acts as a sensitizer to
radiotherapy and chemotherapy. In cancers of the prostate, breast, brain, colon, ovarian
and, head and neck, the levels of ROS are higher in comparison to the surrounding normal
tissue [123, 168, 175, 184-190]. This makes these cancer cells more susceptible to ROS
mediated cell death when treated with a combination of manganese porphyrin compounds
and chemo- or radiotherapy, which are involved in generating ROS. Further, accumulation
of MnTE-2-PyP in tumor was found to be 7-fold higher in comparison to the normal tissue,
which contributes to its anticancer effect [190]. In lymphoma, anti-cancer activity was
achieved by manganese porphyrin compounds by suppressing mitochondrial and
glycolytic energy sources of cancer cell [191]. Further, an increase in S-glutathionylation
of p65 subunit of NF-κB by the H2O2 generated by manganese porphyrin compounds
contributes to its anticancer activity [192].
Given that these compounds do not protect tumors from radiation damage and are
effective radioprotectors [172], we need to understand the molecular pathways and
mechanisms through which they work. The consequences of boosting cellular capacity to
convert superoxide to hydrogen peroxide using these compounds can help us further
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understand the redox-sensitive pathways. Identification of the pathways on which these
drugs work would help us further develop these compounds, potentially reverse fibrotic
conditions and use the compounds for other applications.
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Figure 2. Structure of manganese porphyrin compounds used to remove
superoxide and prevent the development of RIF. (A) Structure of MnTE-2-PyP or
BMX-010 (CASRN 219818-60-7, Molecular Weight 965.13). (B) Structure of
MnTnBuOE-2-PyP or BMX-001 (CASRN 1379783-91-1, Molecular Weight 1253.55).
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1.7.

Signaling pathways altered by manganese porphyrin compounds

Similar to SOD enzymes, manganese porphyrin compounds catalyze the conversion of
superoxide molecules to hydrogen peroxide. Hydrogen peroxide has the most prolonged
half-life of all ROS and is less reactive in comparison to superoxide [193]. An increase in
hydrogen peroxide levels can lead to reversible oxidation of cysteine thiols to sulfenic
acids (R-SOH) and sulfinic acid (R-SO2H), and further irreversible post-translational
modification to sulfonic acid (R-SO3H). Alternatively, R-SOH modification can react with
free protein thiols to form intra- or intermolecular disulphide bonds (R-S-S-R/R-S-S-R′) or
is modified by glutathione (GSH) to form S-glutathionylation post-translational modification
[194].
Hydrogen peroxide is a central redox signaling molecule that can diffuse across
membranes and can serve as an “oxidative eustress molecule” at low concentrations (110 nM) or physiological steady-state levels [173, 195]. The term “oxidative eustress”
means normal signaling of oxidative stress and serves as a distinction from excessive
load, “oxidative distress”, which is known to cause oxidative damage [195]. At high
concentrations (>100 nM), hydrogen peroxide can damage cellular structures and activate
cell death pathways. Further, hydrogen peroxide can activate adaptive stress responses
such as the nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathway or nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway [195] or activate
apoptotic pathways for removal of damaged cells [196, 197]. Therefore, manganese
porphyrin compounds can act as oxidants or antioxidants depending on the concentration
used and the cellular microenvironment [168].
Our group has previously shown MnTE-2-PyP treatment inhibits the TGF-β1 signaling
pathway to protect against acute radiation-induced damage [1, 198]. However, the
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mechanism of inhibition of the TGF-β1 signaling pathway is not completely understood.
Further, MnTE-2-PyP and its sister molecules have been shown to inhibit the NF-κB
signaling pathway [192, 199-202], and hypoxia-inducible factor-1 alpha (HIF-1α) [62, 114,
203-205]. Recent reports also suggest that manganese porphyrin compounds can activate
NRF2 signaling in hematopoietic stem cells [206]. Therefore, there could be crosstalk
between these pathways and identification of the early changes in fibroblast cells would
be essential to understand radioprotective mechanisms.

1.8.

The role of the NRF2 signaling pathway in radioprotection

NRF2 or Nuclear factor erythroid 2-related factor 2, is a basic leucine zipper (bZIP)
transcription factor that is responsible for the expression of several downstream targets
such as NQO1, heme oxygenase 1 (HMOX1), glutamate-cysteine ligase catalytic subunit
(GCLc), thioredoxin reductases (TrxR), glutamate-cysteine ligase modifier subunit
(GCLm), glutathione peroxidases (Gpx) and other genes [207-209] that are involved in
redox balance, purine metabolism, pentose metabolism, lipid metabolism, inflammation,
and proteostasis [210, 211].
The NRF2 protein consists of 605 amino acids and 7 recognized NRF2-ECH homology
(Neh) domains (Fig. 3: A). These domains are responsible for interacting with different
binding partners and its role in cellular functioning. Neh1 domain contains the cap “n” collar
– basic-region leucine zipper (CNC-bZIP) region, which interacts and binds to antioxidant
response elements (ARE) DNA elements (5′-TGACXXXGC-3′ or 5′-AGTGAXXCAGCA-3′)
of the downstream targets. The Neh1 domain also interacts with the small
masculoaponeurotic fibrosarcoma (sMaf) proteins (MafF, MafG, and MafK), which are
NRF2 dimerization partners. The DLG and ETGE amino acid motifs of Neh2 domain
interacts with the double glycine repeat (DGR) motif of the Kelch domain of KEAP1, which
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is the negative regulator of NRF2. KEAP1 is a redox-sensitive adaptor protein, which binds
to the Cul3/Rbx1/E2/ubiquitin ligase complex that ubiquitinates seven lysine residues of
NRF2 in Neh2 domain and subjects it to proteasomal degradation. Neh3, Neh4 and Neh5
domains are transactivation domains of NRF2 that bind to CREB-binding protein (CBP),
ras-related C3 botulinum toxin substrate 3 (RAC3), and chromodomain Helicase DNA
Binding Protein 6 (CHD6) proteins. The Neh6 domain is a serine-rich region that binds to
β-transducing repeat-containing protein (β-TrCP), which negatively regulates NRF2
stability independent of KEAP1, upon glycogen synthase kinase-3β (GSK3β) mediated
phosphorylation of DSGIS and DSAPGS peptide motifs of Neh6 domain. Phosphorylation
of the Neh6 domain leads to the recruitment of Skp1-Cul1-F-box protein (SCF) ubiquitin
ligase complex which regulates NRF2 proteasomal degradation. The Neh7 domain
interacts with retinoid X receptor α to repress NRF2 transcriptional activity. KEAP1, Kelch
domain, that interacts with NRF2, also interacts with Sequestosome-1 (SQSTM1), which
is a scaffold for binding of several proteins and regulates autophagy. The intervening
region (IVR) domain of KEAP1, is redox sensitive and the cysteine residues (C272 and
C288) of this domain are subjected to several different post-translational modifications. The
broad complex, tramtrack and bric-à-brac (BTB) domain, is involved in KEAP1
dimerization and the C151 residue of this domain also appears to be a key redox sensor
(Fig. 3: B).
Canonical NRF2 signaling is maintained at homeostatic levels through its cytoplasmic
binding partner KEAP1, which prevents its translocation to the nucleus and ensures
proteasomal degradation [212-214]. The non-canonical NRF2 signaling pathway is
regulated by changes in protein levels and phosphorylation (Ser349) of SQSTMq, which
is also known as p62 [212]. SQSTM1 competitively binds to KEAP1, which leads to KEAP1
degradation through autophagy and an increase in NRF2 levels [215]. SQSTM1, is a
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ubiquitin-binding protein that is involved in the regulation of cell signaling, oxidative stress,
and autophagy [216, 217]. Importantly, lack of SQSTM1 or impairment of autophagy can
result in the accumulation of damaged mitochondria and increased production of ROS that
can further enhance fibroblast activation or formation of myofibroblast phenotype [218222].
The role of NRF2 in response to radiation exposure in healthy tissue has been reviewed
by Cameron et al., in 2018, and it highlights the variability in different human tissues [223,
224]. The NRF2 signaling pathway plays a significant role in fibroblast reprogramming and
the expression of a senescence-promoting matrix [225]. In the context of radiation
exposure and lung fibrosis, NRF2 is involved in the crosstalk and suppression of the
transforming growth factor-beta 1 (TGF-β1) signaling pathway, which is the most well
studied pro-fibrotic pathway [226-228]. An active NRF2 protein is known to form a nuclear
complex with pSMAD3 at the CAGA site in the proximal promoters of TGF-β target genes
and suppresses their expression [229]. The crosstalk between SIRT1 and the NRF2
pathway forms a positive feedback loop to inhibit the expression of fibronectin (FN) and
TGF-β1 [230]. Conversely, loss of NRF2 promotes TGF-β/Smad signaling that induces
activating transcription factor 3 (ATF3) mediated suppression of NRF2 target genes. this
crosstalk with the TGF-β1 signaling could play a role in the development of RIF. Previously
observed radioprotective properties of MnTE-2-PyP and changes in TGF-β1 signaling
pathway could be linked to changes in the NRF2 pathway in prostate fibroblast cells.
Therefore, we hypothesize that MnTE-2-PyP protects the prostate from RIF by activating
the NRF2 signaling pathway.
The goal of this thesis is to investigate the molecular pathways and anti-fibrotic
mechanisms of manganese porphyrin compounds such as MnTE-2-PyP. We will probe
the molecular pathways that will help explain the radioprotective effects of these
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compounds in normal tissue and radiosensitive effects in cancer cells. We want to use this
information to further enhance and optimize the use of manganese porphyrin compounds
in radioprotection, chemoprotection and its use in other chronic diseases.
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Figure 3. NRF2 and KEAP1 binding partners and domain functions. (A) Human
NRF2 protein comprises of 7 Neh domains. Their respective binding partners are
shown. (B) Human KEAP1 protein comprises 4 domains. Their respective binding
partners are shown. Neh, Nrf2-ECH homology; CNC-bZIP, cap “n” collar - basic-region
leucine zipper; NTR, N-terminal region; BTB, Broad complex, Tramtrack and Bric-àBrac ; IVR, intervening region ; and CTR, C-terminal region.
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Chapter 2.

2.1.

Materials and methods

Cell lines and tissue culture

Mouse primary prostate fibroblast (MPF) cells were isolated from the prostate tissue of 6–
8-week-old C57BL/6J mice (wild type) or C57BL/6J Nfe2l2tm1Ywk (NRF2) knockout mice,
as previously published [1]. Briefly, prostates were minced and digested with 5 mg/mL
collagenase I for 30 min at 37 °C (17100017, ThermoFisher). These cells were cultured in
DMEM

media

supplemented

with

10%

fetal

bovine

serum

(FBS),

1%

penicillin/streptomycin and 1% nonessential amino acids [1]. MPF cells were pretreated
with 30 μM MnTE-2-PyP for 24 hours, followed by 2 Gy radiation exposure and then
collected 24 hours post-irradiation. Immortalized healthy human prostate fibroblast cells
(P3158) were obtained from Dr. McDonald J. Tyson. Immortalization was performed by
using pBABE-hygro-hTERT plasmid, a gift from Dr. Robert Weinberg (Addgene, plasmid
#1773, Cambridge, MA, USA). These cells were cultured in RPMI-1640 medium,
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Normal
human primary prostate fibroblast (HPrF) cells were purchased from ScienCell Research
Laboratories (4430). HPrF cells were cultured in Fibroblast Medium (2301) on poly-Llysine coated flasks (2 µg/cm2) according to the protocol provided by ScienCell Research
Laboratories. KEAP1 knockout mouse embryonic fibroblast cells and wild type cells were
derived from C57BL6 mice and were a kind gift from Dr. Thomas Kensler’s laboratory at
Fred Hutchinson Cancer Research Center (Dr. Nobunao Wakabayashi) [231]. All
fibroblast cells were treated with or without 30 μM MnTE-2-PyP, 24 hours before radiation
exposure 2-3 Gy unless stated otherwise.
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2.2.

Real-time quantitative PCR (RT-qPCR)

RNA was isolated from P3158 cells with the ZR RNA MicroPrep RNA isolation kit (R1065,
Zymo Research) according to the manufacturer’s protocol. For quantitative analysis of
mRNA expression, comparative real-time PCR was performed with the use of Power
SYBR Green RNA-to-CT 1 step kit (4389986, ThermoFisher). Quantitative PCR was
performed under the following conditions: 48 ºC for 30 min, 95 ºC for 10 min, then 40
cycles with 95 ºC for 15 sec and 60ºC for 1 min. PCR primers obtained from Invitrogen
used for experiments are listed below in Table. 2.
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Table 2. List of primers used for RT-qPCR.
Gene

Forward Primer (5′-3′)

Reverse Primer (5′-3′)

Human
RPLPO

GTCCTCGTGGAAGGCCC

AGGAGAGACAGGGAGCTCAG

Human
NQO1

CCTTGTGATATTCCAGAGTGGC CCAGGCGTTTCTTCCATCCT

Human
NRF2

GTTGCCCACATTCCCAAATC

AAGTGACTGAAACGTAGCCG

Human
GSTA4

GAGTGGACTCCAGAAAGCCTG

TCATCAAACTCGACTCCGGC

Human
FGF9

CCTGGGTCAGTCCGAAGC

CAGAATGCCAAATCGGCTGTG

Human
FGF10

AAGGCAACGTTTGTGGATGC

TCTGCAACGTGTCTTTGCCT

Human
POSTN

TCCCCGTGACTGTCTATAAGCC TGGTGACCTTGGTGACCTCTT

Human
VITRIN

ATGTCAGCCTGGGACTTGTT

AGGAGCTGCTTCTGGATTCG

Human
COL3A1

CTTCTCTCCAGCCGAGCTTC

TGTGTTTCGTGCAACCATCC

Human
COL1A2

ACAAGGCATTCGTGGCGATA

ACCATGGTGACCAGCGATAC

Human
COL1A1

GGACACAGAGGTTTCAGTGGT

GCACCATCATTTCCACGAGC

Human
COL5A1

GACAAGAAGTCCGAAGGGGC

TAGGAGAGCAGTTTCCCACG

Human
COL6A2

CTCCTCGGGACCAGGACTT

GGTGTCCAGCACGAAGTACA

Mouse
RPLPO

GCAGGTGTTTGACAACGGCAG

GATGATGGAGTGTGGCACCGA

Mouse
NQO1

GGTAGCGGCTCCATGTACTC

CGCAGGATGCCACTCTGAAT

Mouse
POSTN

TCTTGCAAAAAGACACACCTG

TCTGGCCTCTGGGTTTTCAC

Mouse
COL3A1

TGACTGTCCCACGTAAGCAC

GAGGGCCATAGCTGAACTGA
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2.3.

Collagen contraction assay

The same procedure was followed for the collagen contraction assay, as previously
published [1]. Briefly, human or mouse prostate fibroblast cells (1 x 105) were embedded
in 2 mg/mL of rat tail collagen (354249, Corning) discs on low-attachment 24-well plates.
After 8 hours of incubation, the collagen discs were observed for contraction and imaged.
Areas of collagen discs were measured using ImageJ.

2.4.

Western blotting

Cell lysates were prepared using 1x Cell Lysis Buffer (9803S, Cell Signaling Technology).
Cell lysates (40-80 μg) were separated by electrophoresis using Bolt™ 4-12% Bis-Tris
plus gels (NW04120BOX, ThermoFisher). Gels were transferred onto nitrocellulose
membranes for blotting using the iBlot™ Transfer Stack (IB301002) and the iBlot 2 Dry
Blotting System (ThermoFisher). For COL3A1 blotting, polyvinylidene difluoride (PVDF)
membranes were used for transfer. To measure protein loading and transfer, we used
Ponceau S staining for nitrocellulose membranes and a reversible protein stain kit for
PVDF membranes (1858784, ThermoFisher). Blots were incubated with blocking buffer
5% nonfat dried milk in Tris Buffered Saline with Tween 20 (TBST). Primary antibody
incubation was performed overnight in 3% nonfat dried milk in TBST. Primary antibodies
used in this paper include; NRF2 (ab62352), p-SQSTM1 (Ser349) (ab211324), SQSTM1
(ab56416), SOD2 (ab13533), SOD2 (acetyl K68) (ab137037), SOD2 (acetyl K122)
(ab214675), NOX4 (ab133303), and α-smooth muscle actin (ab5694) were obtained from
Abcam (Cambridge, MA, US), NQO1 (NB200-209) was obtained from Novus Biological,
and KEAP1 (D6B12) was obtained from Cell Signaling Technology, Inc. (Danvers, MA,
USA). Secondary horseradish peroxidase-conjugated antibody used was anti-rabbit
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(A24537, ThermoFisher), anti-mouse (A24524, ThermoFisher). Pierce ECL Western
Blotting Substrate (80196, ThermoFisher) and SuperSignal™ West Dura Extended
Duration Substrate (34076, ThermoFisher).

2.5.

Gene silencing

Transfections of siRNAs were performed using Lipofectamine RNAiMAX Transfection
Reagent (13778150, ThermoFisher) according to the manufacturer's instructions for
transfecting adherent cells. Briefly, transfection complexes were formed at RT using 20 nM
of siRNA, 7.5 μL of RNAiMAX, and 500 μL Opti-MEM I – Gibco (31985-062,
ThermoFisher). Transfection complexes were added, and the mix was incubated with cells
for 24 h using standard cell culture conditions. Negative control scrambled siRNA (Scr)
(4390843, Ambion), Nfe2l2 (NRF2) siRNA (4392421, Ambion), NQO1 siRNA (43261843,
Invitrogen), and SQSTM1 siRNA (AM16708, ThermoFisher) were used in the
experiments.

2.6.

NAD+/NADH assay

To measure changes in NAD+/NADH levels, we used the NAD+/NADH-Glo™
Bioluminescent Assay (G9071, Promega). In the presence of NADH, a reductase provided
with the assay reduces a proluciferin reductase substrate to luciferin. Luciferin is quantified
using Ultra-Glo™ Recombinant luciferase and the light signal produced is proportional to
the amount of NAD+ or NADH in the sample. P3158 cells were pretreated with MnTE-2PyP (30 µM) for 24 hours before radiation (5 Gy) and collected 48 hours after radiation.
5000 cells were suspended in 50 µl of PBS and mixed with 1% dodecyltrimethylammonium
bromide solution as directed by the protocol by Promega’s NAD/NADH-Glo™ Assay. After
acid-base treatment of samples, NAD+ and NADH were separately measured 60 minutes
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after the addition of the 100 µl of NADP/NADPH-Glo™ detection reagent. Luminescence
was recorded using the Infinite M200 Pro plate reader (Tecan).

2.7.

Sirtuin activity assay

To measure changes in sirtuin activity, we used BioVision’s sirtuin activity assay kit
(Fluorometric, K324-100, BioVision). Nuclear extracts were made 48 hours after radiation
using the CelLytic NuCLEAR extraction kit (NXTRACT-1KT, Sigma), and 1 μg of nuclear
extract was used to measure sirtuin activity. Trichostatin A is added to the reaction to
specifically inhibit the activity of HDAC’s in samples. Mitochondrial extracts were made
using the Mitochondria Isolation Kit for Cultured Cells (89874, ThermoFisher). Briefly, 1.5
× 106 cells/ T75 flask were seeded with MnTE-2-PyP (30 µM) and after radiation exposure,
cells were collected for isolation of nuclear, cytoplasmic, and mitochondrial fractions
according to manufacturer’s instructions. Samples were mixed with a sirtuin activity buffer
containing DTT ± TSA according to the protocol from BioVision’s sirtuin activity assay kit.
Fluorescence was measured using the Infinite M200 Pro plate reader (Tecan) at Ex/Em =
400/505 nm. Background control reading was subtracted from sample reading, and the
corrected sample reading was measured against the AFC standard curve.

2.8.

Dihydroethidium (DHE) assay

To measure superoxide levels and total ROS, cells were stained by dihydroethidium
(D11347, DHE, 5 μM) for 20 min at 37 °C in the dark and then subjected to flow cytometric
analysis using a LSRII Green 532 Flow Cytometer (BD Biosciences). To measure
superoxide specifically, 405/570 nm excitation/emission was used. Data was analyzed
using FACSDiVa analysis software (BD Biosciences). To measure total ROS, 488/540 nm
excitation/emission wavelengths were used.
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2.9.

NRF2 enzyme-linked immunosorbent (ELISA) assay

NRF2 activity was determined using the TransAM NRF2 assay (50296, Active Motif)
according to the manufacture’s protocol. Briefly, nuclear extracts (5 μg) were incubated
with ARE consensus site oligonucleotides (5′-GTCACAGTGACTCAGCAGAATCTG-3′);
immobilized to 96-well plates. Bound protein was detected with an antibody specific to
DNA-bound NRF2 and visualized by a colorimetric reaction catalyzed by horseradish
peroxidase-conjugated secondary antibody, and absorbance was measured at 405 nm
using the Infinite M200 Pro plate reader (Tecan).

2.10.

NRF2 Electrophoretic mobility shift assay (EMSA)

For studying the DNA binding activity of NRF2, nuclear extracts were made as described
[232, 233]. Promega Gel Shift Assay Core System (E3050, Promega) and used NRF2
consensus oligonucleotide from NF-E2 gel shift oligonucleotides product from Santa Cruz
Biotechnology (sc-2527). Thirty-five pmol of each consensus oligonucleotide was labeled
by P32-ATP by T4-polynucleotide kinase according to the Promega protocol. After
purification of labeled consensus oligonucleotide, 10 µg nuclear protein was incubated
with the oligonucleotides and run in 6% TBE gel (EC6265BOX, ThermoFisher) according
to the Promega gel shift assay system protocol. Then the gels were air-dried overnight
using Model 583 gel dryer backing cellophane (1650963, BIO-RAD) and a gel drying
cassette. The dried gel with the cellophane were then exposed to film. Films were scanned
and the densitometry analyses of the scanned images were performed using ImageJ.
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2.11.

ROS-GLO H2O2 assay

Hydrogen peroxide (H2O2) generated by MnTE-2-PyP was measured using the ROS-GLO
H2O2 assay (G8820, Promega) as previously described [234]. Briefly, HPrF cells (1 × 104
cells/well in 70 µl of HPrF media) were seeded in a Nunclon 96 Flat White Plate
(ThermoFisher). MnTE-2-PyP time course treatment was performed by the addition of 10
µl of MnTE-2-PyP (30 µM) or PBS. Six hours before measurement of H2O2, 20 µl H2O2
substrate and H2O2 dilution buffer were added to each well. At the end of the MnTE-2-PyP
time course treatment, 100 µl ROS-GLO™ Detection Solution was added to each well and
all samples were incubated at room temperature for 20 min. Luminescence was read by
the Infinite M200 Pro Plate Reader (Tecan) using an integration time of 1000 ms.

2.12.

SOD2 in-gel activity assay

SOD2 activity was monitored with non-denaturing gel electrophoresis, as previously
described [235]. Briefly, whole-cell protein lysate (100 μg) were separated in a 10% nativePAGE gel and stained by riboflavin, nitroblue tetrazolium, and TEMED. SOD2 activity was
differentiated from SOD1 activity by inhibiting SOD1 activity with the use of sodium
cyanide in the staining solution. SOD2 activity bands were developed overnight under
exposure of light. Images were taken and the density of the band was measured to obtain
the relative SOD2 activity.

2.13.

Xanthine oxidase - SOD activity assay

SOD activity assay was measured in mitochondrial extracts using a xanthine oxidase SOD activity assay kit (K335-100, BioVison). Briefly, 5 μg of mitochondrial extract in 20 μl
of cell lysis buffer was pipetted into each sample wells, and 200 µl of the WST-1 working

38
solution and 20 µl of the SOD enzyme working solution were added to the sample wells
and mixed thoroughly. The solution was incubated at 37°C for 20 minutes. The
inhibition/reduction activity of SOD was estimated by measuring absorbance at 450 nm
using the Infinite M200 Pro plate reader (Tecan).

2.14.

Cell size analysis

Fibroblasts were seeded at 1 × 105 cells/T-25 flask. Cells were treated with PBS, MnTE2-PyP (30 µM) and siRNA (Scr and NRF2) while seeding. Cells were grown for 5 days in
37°C and 5% CO2 humidified incubator. Images (5-10 images/flask) of each flask at
different positions were taken using the Leica inverted phase-contrast microscope. Images
were imported into ImageJ and approximately 100 cell borders were manually traced per
treatment group. Areas of cells were measured using ImageJ and relative areas of the
treatment groups were analyzed with GraphPad Prism 7 software.

2.15.

RNA sequencing (RNA-Seq)

T25 flask were seeded with mouse primary prostate fibroblast (1 × 106) cells in the
presence of 30 μM MnTE-2-PyP or an equal volume of PBS. The next day, cells were
either sham irradiated or treated with 2 Gy of X-rays (Rad Source RS-2000). 24 hours
after irradiation, cells were harvested and washed two times with 1X PBS. Total cellular
RNA was isolated using Quick-RNA™ MiniPrep (Plus) kit of Zymo Research following the
manufacture’s protocol after genomic DNA removal and DNase treatment. The
concentration and quality of total RNA was measured by Infinite M200 Pro plate reader
(Tecan). Total RNA having a 260/280 ratio ~2.0 was used for further experiments. Total
RNA was sent to City of Hope, CA for RNA sequencing. Sample quality control was
performed by Bioanalyzer RNA6000 Nano ChIP. The sequencing library was prepared by
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using Illumina Stranded RNA-seq library preparation protocol. Quality control of the
sequencing library was ensured by Qubit. RNA sequencing was done by RNA-seq
Ribozero stranded protocol, which removes ribosomal RNA to enhance the mRNA signal
in HiSeq 2500 Fast mode SE50.

2.16.

Mitochondrial function assays with MitoPlates S-1

We used Biolog’s MitoPlates S-1 (14105, Biolog) plates containing preloaded substrates
to study the effects of substrates on mitochondrial function. P3158 cells were seeded in
the presence of PBS or 30 μM MnTE-2-PyP. The next day, cells were exposed to 3 Gy
radiation and then cultured for 5 days before collection. Plates were prewarmed to room
temperature, and Saponin stock solution (24x, 2.4 mg/ml) was made before cell
preparation. Assay mix was made according to protocol and 30 µl of assay mix was
distributed in each well. Plates were incubated at 37° C for 1 hour to allow substrates to
dissolve fully. We used P3158 cells after trypsinization and washing with PBS. Cell pellets
were resuspended in 5 ml of 1x Biolog MAS and filtered through a 70-micron nylon filter.
After cell counting, 20,000 cells per 30 µl were dispensed in each well. To record the rates
of dye reduction in the wells, the MitoPlate without lid was loaded into the Infinite M200
Pro plate reader (Tecan), set to read absorption at 590 nm every 15-minutes for 2 hours
at 37º C.

2.17.

Oxidative stress TF activation profiling plate array

We used Signosis’s oxidative stress transcription factor (TF) activation profiling plate array
(FA-1005, Signosis) to assess the impact of hydrogen peroxide generation by MnTE-2PyP on the activity of 16 oxidative stress sensitive TFs. Nuclear extracts were made from
P3158 cells using the CelLytic NuCLEAR extraction kit (NXTRACT-1KT, Sigma).
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According to the manufacture’s protocol, reagents for the experiment were prepared
before starting and maintained at the instructed temperatures. We made 30 µl of TF DNA
complex using 5 µg of nuclear extract from every sample with 15 µl TF binding buffer mix,
3 µl TF Probe mix for oxidative stress and ddH2O. TF DNA complex were incubated at
room temperature for 30 minutes. Free probes were separated from TF DNA complex and
eluted according to the manufacturer’s protocol. The hybridization of the eluted probes
with the hybridization plate was performed at 42º C for overnight. The captured DNA probe
is further detected with streptavidin-HRP conjugate system after washing and incubation
steps. Luminescence is measured 15 minutes after the addition of the substrate using the
Infinite M200 Pro plate reader (Tecan), set integration time to 1 second. The activity of
TFs is shown by the relative light units measured for every sample.

2.18.

Statistical analysis

All statistical tests were performed using the GraphPad Prism 8 software. Differences
were determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple
comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes
a significant and the symbol (ns) denotes a non-significant difference as compared to the
control (PBS) group. Data were obtained from at least 3 independent experiments unless
otherwise stated and bars in the figures represent mean ± SEM.
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Chapter 3.

3.1.

Results

MnTE-2-PyP treatment and radiation exposure-mediated changes in gene

expression

To understand the signaling pathways associated with fibroblast activation and formation
of the myofibroblast phenotype, and the mechanisms associated with the prevention of
prostate radiation-induced fibrosis, our laboratory performed RNA Sequencing (RNA-Seq)
of mouse primary prostate fibroblast cells. Cells were pretreated with either PBS or 30 μM
MnTE-2-PyP a day before radiation exposure (2 Gy) and then collected 24 hours later for
RNA isolation. After performing RNA-Seq analysis, changes in several different fibrotic
and non-fibrotic gene expression was observed (data not shown).
To confirm and validate the gene expression changes from the RNA-Seq data, we
performed RT-qPCR analysis of NQO1, GSTA4, FGF9, and FGF10 mRNA levels which
could play a role in the fibrotic process. RNA-Seq data indicated NQO1, GSTA4, FGF9
and FGF10 are among the top 20 genes upregulated by MnTE-2-PyP treatment. NADPH
quinone dehydrogenase 1 (NQO1) is a cytoprotective protein involved in the detoxification
of cells when under stress. Glutathione s-transferase alpha 4 (GSTA4), is involved in
cellular defense against toxic, carcinogenic, and pharmacologically active electrophilic
compounds. Fibroblast growth factor 9 (FGF9) and fibroblast growth factor 10 (FGF10)
are members of the fibroblast growth factor (FGF) family of proteins. FGF family members
possess broad mitogenic and cell survival activities and are involved in a variety of
biological processes, including embryonic development, cell growth, morphogenesis,
tissue repair, tumor growth, and invasion.
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RT-qPCR analysis of NQO1, GSTA4, FGF9, and FGF10 mRNA levels in human prostate
fibroblast cells showed that MnTE-2-PyP upregulated NQO1 and FGF10 expression (Fig.
4: A, D). Upon MnTE-2-PyP treatment, NQO1 levels increase by ~2.4-fold (Fig. 4: A), and
FGF10 (Fig. 4: D) increases by ~2.8-fold in comparison to PBS treated samples. Radiation
exposure does not cause a significant increase in NQO1 and FGF10 mRNA levels (Fig.
4: A, D). Further, there was no significant increase in GSTA4 and FGF9 expression upon
MnTE-2-PyP treatment or radiation exposure (Fig. 4: B, C) in human prostate fibroblast
cells.
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Figure 4. MnTE-2-PyP treatment and radiation exposure mediated changes in
gene expression. (A) Relative NQO1 mRNA levels in P3158 cells. (B) Relative GSTA4
mRNA levels in P3158 cells. (C) Relative FGF9 mRNA levels in P3158 cells. (D)
Relative FGF10 mRNA levels in human primary prostate fibroblast (HPrF) cells.
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s
test for multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005)
denotes a significant and the symbol (ns) denotes a non significant difference as
compared to the control (PBS) group. Data were obtained from 3 independent
experiments, bars in the figures represent mean ± SEM.
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3.2.

MnTE-2-PyP treatment and radiation exposure-mediated changes in

extracellular matrix gene expression

The extracellular matrix (ECM) is a three-dimensional network of extracellular
macromolecules, such as collagen, enzymes, and glycoproteins, which provide structural
support to surrounding cells. Fibrotic tissue post-irradiation correlates with an increase in
the ECM proteins that make the surrounding tissue stiffer and sometimes is associated
with tissue scarring. Excessive deposition of ECM by myofibroblast cells leads to improper
tissue functioning and is the cause for some of the side effects observed in prostate cancer
patients following radiation therapy. The excessive ECM deposition builds up over long
periods of time (months to years) upon myofibroblast cell formation. Therefore, the side
effects of radiation therapy are often observed years after initial radiation exposure, and
the side effects progressively worsen over time.
To test the expression of these ECM proteins upon radiation exposure and MnTE-2-PyP
treatment, we selected some of the ECM genes from our RNA-Seq data, which showed
downregulation upon MnTE-2-PyP treatment and performed RT-qPCR analysis in human
prostate fibroblast cells. ECM genes selected for RT-qPCR analysis included POSTN,
VITRIN, COL3A1, COL1A2, COL1A1, COL5A1, and COL6A2. POSTN expression was
significantly reduced with MnTE-2-PyP treatment, and the level of increase post-radiation
exposure was lower due to MnTE-2-PyP treatment (Fig. 5: A). VITRIN expression was
significantly higher post-radiation exposure and the MnTE-2-PyP treatment did not show
a significant increase in comparison to the PBS treated group (Fig. 5: B). COL3A1
expression was significantly lower in MnTE-2-PyP treated groups, with and without
radiation exposure, in comparison to the PBS treated group (Fig. 5: C). COL1A2, COL1A1,
COL5A1 and COL6A2 did not show a significant change either with radiation or MnTE-2PyP treatment in human prostate fibroblast cells (Fig. 5: D-G). Possibly, changes in
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expression of COL1A2, COL1A1, COL5A1 and COL6A2 may take a longer time upon
MnTE-2-PyP treatment or require a higher radiation dose to fully observe significant
differences. Overall, the data indicate that MnTE-2-PyP treatment may be involved in
regulating signaling pathways leading to specific downregulation of certain ECM genes,
POSTN, and COL3A1, after 1-2 days of MnTE-2-PyP treatment in human prostate
fibroblast cells.
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Figure 5. MnTE-2-PyP treatment and radiation exposure mediated changes in
extracellular matrix gene expression. (A) Relative POSTN mRNA levels in P3158
cells. (B) Relative VITRIN mRNA in P3158 cells. (C) Relative COL3A1 mRNA levels in
P3158 cells. (D) Relative COL1A2 mRNA levels in P3158 cells. (E) Relative COL1A1
mRNA in P3158 cells. (F) Relative COL5A1 mRNA levels in P3158 cells. (G) Relative
COL6A2 mRNA levels in P3158 cells. Differences were determined by using a 1-way
ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol (*p
< 0.05, **p < 0.005, ***p < 0.0005) denotes a significant and the symbol (ns) denotes
a non significant difference as compared to the control (PBS) group. Data were
obtained from 3 independent experiments, bars in the figures represent mean ± SEM.
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3.3.

MnTE-2-PyP treatment and radiation exposure mediated changes in gene

expression in mouse primary prostate fibroblast cells

We observed significant changes in gene expression of NQO1, POSTN, and COL3A1 in
human prostate fibroblast cells (P3158). Therefore, we were interested in testing and
confirming these results in mouse primary prostate fibroblast cells as we had only one
replicate of RNA-Seq data from these cells. In mouse primary prostate fibroblast cells, we
observed similar RT-qPCR results for NQO1, POSTN, and COL3A1 expression, as
observed in human prostate fibroblast cells. MnTE-2-PyP caused a significant increase in
NQO1 mRNA levels, and a significant decrease in POSTN and COL3A1 levels, when
compared to the PBS treated samples (Fig. 6: A-C).
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Figure 6. MnTE-2-PyP treatment and radiation exposure mediated changes in
gene expression in mouse primary prostate fibroblast cells. (A) Relative NQO1
mRNA levels. (B) Relative POSTN mRNA. (C) Relative COL3A1 mRNA levels.
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s
test for multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005)
denotes a significant and the symbol (ns) denotes a non-significant difference as
compared to the control (PBS) group. Data were obtained from 3 independent
experiments, bars in the figures represent mean ± SEM.
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3.4.

MnTE-2-PyP treatment and radiation exposure mediated changes COL3A1

protein levels in human prostate fibroblast cells

Collagen, type III, alpha 1 (COL3A1), is one of the fibrillar collagens and is found as a
major structural component in hollow organs such as large blood vessels, uterus, and
bowel. Since we observed a significant decrease in COL3A1 mRNA levels in both human
and mouse prostate fibroblast cells, we wanted to determine if these results correlated
with COL3A1 protein levels upon MnTE-2-PyP treatment. Further, we hypothesized that
the increase in COL3A1 levels after radiation exposure would be much higher and
accumulate over a more extended period. Immunoblotting results of human prostate
fibroblast cells (P3158 cell) whole-cell lysate revealed that MnTE-2-PyP causes a
significant decrease in COL3A1 protein levels (Fig. 7: A-B). Radiation exposure showed
an early trend towards an increase in COL3A1 protein levels, and this was not a significant
increase as we looked at the whole-cell lysate at 48 hours after radiation exposure.
However, this data indicates that the change in mRNA levels observed after MnTE-2-PyP
treatment correlates with changes in the expression of ECM proteins such as COL3A1.
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Figure 7. MnTE-2-PyP treatment and radiation exposure mediated changes
COL3A1 protein levels in human prostate fibroblast cells. (A) Immunoblotting
analysis of COL3A1 levels in P3158 Cells. (B) Quantification of COL3A1 levels in
whole-cell lysate from immunoblot in panel A. Differences were determined by using a
1-way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The
symbol (*p < 0.05, **p < 0.005) denotes a significant and the symbol (ns) denotes a
non-significant difference as compared to the control (PBS) group. Data were obtained
from 3 independent experiments, bars in the figures represent mean ± SEM.
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3.5.

MnTE-2-PyP treatment and radiation exposure mediated changes in NRF2

signaling pathway downstream targets in RNA-seq data

In our RNA-seq data, we observed NQO1 to be one of the top 15 most significantly
upregulated genes by MnTE-2-PyP and is a direct downstream target of NRF2 mediated
transcriptional expression. Confirmation of an increase in NQO1 mRNA in mouse and
human prostate fibroblast cells suggested that activation of the NRF2 pathway by MnTE2-PyP may be responsible for the upregulation of NQO1. To investigate the activation of
the NRF2 signaling pathway, we first examined the expression levels of other NRF2
downstream targets in the RNA-Seq data. There are several downstream targets of the
NRF2 pathway; however, in mouse prostate fibroblast cells, we observed an increase in
Nqo1, Gsta4, Cyp1b1, Gstm1, Mgst1, Il6, Gstt1, Ugt1a7c, Fth1, Smad6, Cav1, Fgf7,
Gsta3, Gclc, Gclm, Hmox1 and Mgst3, in MnTE-2-PyP treated groups. This increase in
downstream targets ranged from a ~1.4-fold to ~2.5-fold in comparison to the PBS treated
group in our RNA-Seq data (Table 3). Increase in expression of genes such as Gsta4,
Gstm1, Mgst1, Gstt1, Gsta3, Gclc, Gclm, and Mgst3, are known to contribute towards a
reduction in overall hydrogen peroxide levels. Further, the RNA-Seq data indicated that
radiation exposure did not cause an activation of the NRF2 pathway (Table 3). This
signature of an increase in NRF2 pathway activation is also seen in the MnTE-2-PyP
treated group exposed to radiation (2 Gy). Further, changes in some of the other
transcriptional targets (fibrotic and non-fibrotic targets) seen in the RNA-Seq data maybe
indirectly connected to the changes in the functional consequences of the NRF2 pathway
activation.
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Table 3. MnTE-2-PyP treatment and radiation exposure mediated changes in
NRF2 signaling pathway downstream targets in RNA-Seq data. (A) RNA-Seq data
of NRF2 pathway downstream target genes upregulated (fold-change) by MnTE-2-PyP
(T2E) treatment in mouse primary prostate fibroblast cells, n=1.
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NRF2 downstream target genes upregulated upon T2E treatment

PBS

T2E

PBS

T2E

0 Gy

0 Gy

2 Gy

2 Gy

Nqo1

1.0

2.5

-1.0

2.7

Gsta4

1.0

2.5

-1.1

3.2

Cyp1b1

1.0

2.4

-1.0

2.9

Gstm1

1.0

2.1

1.1

2.3

Mgst1

1.0

2.1

1.1

2.4

Il6

1.0

2.0

1.2

2.4

Gstt1

1.0

1.9

-1.0

1.9

Ugt1a7c

1.0

1.9

1.1

2.1

Fth1

1.0

1.8

1.0

2.3

Smad6

1.0

1.7

-1.1

1.5

Cav1

1.0

1.6

-1.0

1.3

Fgf7

1.0

1.6

1.1

1.6

Gsta3

1.0

1.6

1.1

1.7

Gclc

1.0

1.5

1.1

1.8

Gclm

1.0

1.5

1.0

1.4

Hmox1

1.0

1.4

1.1

1.6

Mgst3

1.0

1.4

1.2

1.6

Genes
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3.6.

MnTE-2-PyP treatment and radiation exposure mediated changes in levels of

the NRF2 signaling pathway of prostate fibroblast cells

The NRF2 signaling pathway is a critical antioxidant pathway that is involved in
cytoprotection and radioprotection. There are several mechanisms through which the
NRF2 pathway is regulated of which the canonical pathway involving KEAP1 and the noncanonical pathway involving SQSTM1 are best established. Therefore, to test the
activation of the NRF2 signaling pathway upon MnTE-2-PyP treatment, we performed
immunoblotting experiments and identified changes in protein levels of NRF2, KEAP1, pSQSTM1, SQSTM1, and NQO1. KEAP1 is a negative regulator of NRF2 and is a
cytoplasmic binding partner of NRF2. Changes in SQSTM1 and its phosphorylation is also
reported to be involved in NRF2 pathway activation [212, 236].
Further, we tested if the changes in NQO1 mRNA levels correlate with the changes in
NQO1 protein levels due to NRF2 pathway activation. In whole-cell lysates of prostate
fibroblast cells (P3158 cells), a significant increase (~1.8-fold) in NRF2 levels in MnTE-2PyP treated groups with and without radiation was observed after five days (Fig. 8: A-B).
We detected a decrease in KEAP1 levels, an increase in total SQSTM1 levels, and an
increase in phosphorylation of SQSTM1 (Ser349) protein, which is involved in the
canonical and non-canonical NRF2 signaling pathway activation mechanisms (Fig. 8: A).
Correspondingly, NQO1 levels significantly increased with MnTE-2-PyP treatment (Fig. 8:
A, C). This data indicates that MnTE-2-PyP is involved in NRF2 pathway activation
through the canonical and non-canonical pathways.
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Figure 8. MnTE-2-PyP treatment and radiation exposure mediated changes in
levels of NRF2 signaling pathway of prostate fibroblast cells. (A) Immunoblotting
analysis of whole-cell lysate for NRF2, KEAP1 (Canonical pathway), phosphoSQSTM1 (Ser349, Non-canonical pathway), SQSTM1 and NQO1 from P3158 cells.
(B) Quantification of NRF2 levels from immunoblot in panel A. (C) Quantification of
NQO1 levels from immunoblot in panel A. Differences were determined by using a 1way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol
(*p < 0.05, ***p < 0.0005) denotes a significant and the symbol (ns) denotes a non
significant difference as compared to the control (PBS) group. Data were obtained from
3 independent experiments, bars in the figures represent mean ± SEM.
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3.7.

MnTE-2-PyP treatment dose required for NRF2 pathway activation

To identify the minimum and maximum dose of MnTE-2-PyP required to activate the NRF2
signaling pathway in vitro, we performed a MnTE-2-PyP treatment dose curve ranging
from 0-30 µM (Fig. 9: A). We found that 48 hours of MnTE-2-PyP treatment caused a
significant increase in NRF2 levels at 10 µM (~1.3-fold), with a maximum increase at 30
µM (~1.7-fold, Fig. 9: A-B). NQO1 levels increased significantly at 5 µM (~1.5-fold), and a
maximum increase in NQO1 was achieved at 30 µM (~1.8-fold) after 48 hours of MnTE2-PyP treatment (Fig. 9: A, C). SOD2, whose expression is in part controlled by the NRF2
pathway, increased significantly at 2.5 µM (~1.5-fold) with a maximum increase at 30 µM
(~2.3-fold, Fig. 9: A, D). However, there could be other signaling pathways or transcription
factors being activated by MnTE-2-PyP treatment that contribute to a significant increase
in SOD2 expression at low doses. To test the significance of NRF2 pathway activation in
the prevention of radiation-induced fibrosis, we selected 30 µM as the MnTE-2-PyP
treatment dose for our experiments because this dose produced the most robust activation
of the NRF2 pathway in vitro.
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Figure 9. MnTE-2-PyP treatment dose required for NRF2 pathway activation. (A)
Immunoblotting analysis for NRF2, NQO1 and SOD2 levels in whole-cell lysate of
P3158 cells treated with 2.5 μM, 5 μM, 10 μM, 20 μM and 30 μM MnTE-2-PyP for 48
h. (B) Quantification of NRF2 levels from immunoblot in panel A. (C) Quantification of
NQO1 levels from immunoblot in panel A. D. Quantification of SOD2 levels from
immunoblot in panel A. Differences were determined by using a 1-way ANOVA followed
by a post hoc Tukey’s test for multiple comparisons. The symbol (**p < 0.005, ***p <
0.0005, ****p < 0.00005) denotes a significant and the symbol (ns) denotes a nonsignificant difference as compared to the control (PBS) group. Data were obtained from
3 independent experiments, bars in the figures represent mean ± SEM.
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3.8.

MnTE-2-PyP treatment time course analysis of NRF2 levels in the nucleus of

prostate fibroblast cells

NRF2 is a transcription factor, and its nuclear localization is required for transcriptional
activity. After an increase in oxidative stress, NRF2 is released from KEAP1, which leads
to its translocation into the nucleus, and increases gene expression of its downstream
targets. The increase in NRF2 nuclear levels can be quick or slow depending on the
mechanism of NRF2 pathway activation. To understand the process and confirm the
activation of the NRF2 pathway by MnTE-2-PyP treatment, we looked at the timedependent increase in NRF2 levels in the nucleus. We observed a significant increase in
the levels of NRF2 nuclear localization within 16 hours of MnTE-2-PyP treatment and a
maximum level (~2.3-fold) of NRF2 within the nucleus at 48 hours (Fig. 10: A-B). NRF2
levels are maintained for at least five days when MnTE-2-PyP is present in the culture
media (Fig. 10: A-B). These results indicate that the NRF2 pathway is activated by MnTE2-PyP treatment within 16 to 48 hours of drug treatment.
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Figure 10. MnTE-2-PyP treatment time course analysis of NRF2 levels in the
nucleus of prostate fibroblast cells. (A) Time course analysis of NRF2 protein level
in nuclear extract after MnTE-2-PyP treatment in P3158 cells. (B) Quantification of
NRF2 levels in nuclear extract from immunoblot in panel A. Differences were
determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple
comparisons. The symbol (*p < 0.05, ***p < 0.0005, ****p < 0.00005) denotes a
significant and the symbol (ns) denotes a non-significant difference as compared to the
control (PBS) group. Data were obtained from 3 independent experiments, bars in the
figures represent mean ± SEM.
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3.9.

MnTE-2-PyP treatment increases NRF2’s DNA binding activity

Enzyme-linked immunosorbent assay (ELISA), is a plate-based assay technique designed
for detecting relative levels of proteins and its ability to bind a given epitope (DNA or
antigen) attached to the plate surface. To validate the activation of NRF2 signaling by
MnTE-2-PyP and NRF2’s capacity to bind antioxidant response elements (ARE) DNA
elements, we performed a NRF2 specific colorimetric ELISA assay containing the NRF2
consensus binding site (5’ – GTCACAGTGACTCAGCAGAATCTG – 3’) immobilized onto
a 96-well plate. Active Nrf2 present in the nuclear extract specifically binds to the
oligonucleotide. In prostate fibroblast nuclear extracts (P3158 cells), we observed a ~1.5fold significant increase in NRF2 binding to ARE DNA elements in MnTE-2-PyP treated
groups (Fig. 11: A). Importantly, radiation exposure, which is known to generate ROS and
increase oxidative stress, did not lead to an activation of the NRF2 signaling pathway in
the prostate fibroblast cells (Fig. 11: A). These results indicate that MnTE-2-PyP is a NRF2
pathway activator drug.
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Figure 11. MnTE-2-PyP treatment increases NRF2’s DNA binding activity. (A)
Quantification of NRF2 DNA binding activity measured using an ELISA for nuclear
extracts from fibroblast cells at 5 days post-irradiation and 6 days post-MnTE-2-PyP
treatment. Differences were determined by using a 1-way ANOVA followed by a post
hoc Tukey’s test for multiple comparisons. The symbol (**p < 0.005, ***p < 0.0005)
denotes a significant and the symbol (ns) denotes a non significant difference as
compared to the control (PBS) group. Data were obtained from 3 independent
experiments, bars in the figures represent mean ± SEM.
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3.10.

Nuclear extracts of prostate fibroblast have increased NRF2-DNA interaction

upon MnTE-2-PyP treatment

Electrophoretic mobility shift assay (EMSA) is an affinity electrophoresis technique used
to study protein–DNA interactions. For visualization purposes, the nucleic acid fragment
is usually labeled with a radioactive label (P32). An increase in NRF2 levels in the nucleus
of fibroblast cells should lead to an increase in the amount of NRF2 binding to the
radiolabeled oligonucleotides containing NRF2 DNA binding sequence. Therefore, we
made nuclear extracts from prostate fibroblast cells (P3158) that were PBS or MnTE-2PyP treated ± radiation (5 Gy) exposed and collected five days later. Our results showed
a significant increase in the size of the NRF2 band (lane 2 and lane 4) in samples treated
with MnTE-2-PyP with or without radiation exposure in comparison to the PBS treated
sample (lane 1, Fig. 12: A-B). We also observed a significant decrease in the NRF2 band
in the samples exposed to radiation (lane 3) in comparison to the PBS treated sample
(lane 1, Fig. 12: A-B). This data indicates that MnTE-2-PyP treatment causes an increase
in NRF2 DNA binding activity and radiation exposure causes a decrease in NRF2 DNA
binding activity. Therefore, radiation exposure does not activate the major antioxidant
signaling pathway, NRF2, and MnTE-2-PyP treatment is required to activate the NRF2
signaling pathway.
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Figure 12. Nuclear extracts of prostate fibroblast have increased NRF2-DNA
interaction upon MnTE-2-PyP treatment. (A) NRF2 DNA binding activity from
nuclear extracts of P3158 cells determined by EMSA. (B) Quantification of NRF2
binding band in panel A. Differences were determined by using a 1-way ANOVA
followed by a post hoc Tukey’s test for multiple comparisons. The symbol (**p < 0.005,
***p < 0.0005, ****p < 0.00005) denotes a significant and the symbol (ns) denotes a
non significant difference as compared to the control (PBS) group. Data were obtained
from 3 independent experiments, bars in the figures represent mean ± SEM.
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3.11.

Time course analysis of NQO1 and NRF2 mRNA levels after MnTE-2-PyP

treatment

To understand the mechanism of the NRF2 signaling pathway activation by MnTE-2-PyP,
and the reason for an increase in NRF2 protein levels in prostate fibroblast cells, we first
checked for changes in NRF2 and NQO1 mRNA levels with a MnTE-2-PyP treatment time
course. A significant increase in NQO1 mRNA can be observed at 24 hours (~1.4-fold),
48 hours (~1.7-fold) and 72 hours (~2.5-fold) of MnTE-2-PyP treatment due to activation
of the NRF2 signaling pathway (Fig. 13: A). However, activation of the NRF2 pathway and
an increase in NRF2 protein levels by MnTE-2-PyP treatment is not associated with an
increase in NRF2 mRNA levels (Fig. 13: B). Therefore, changes in NRF2 protein levels by
MnTE-2-PyP is probably associated with a post-transcriptional mechanism of activation
and not with transcriptional changes of NRF2.
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Figure 13. Time course analysis of NQO1 and NRF2 mRNA levels after MnTE-2PyP treatment. (A) Relative NQO1 mRNA levels in P3158 cells. (B) Relative NRF2
mRNA levels in P3158 cells. Differences were determined by using a 1-way ANOVA
followed by a post hoc Tukey’s test for multiple comparisons. The symbol (*p < 0.05,
**p < 0.005, ****p < 0.00005) denotes a significant and the symbol (ns) denotes a non
significant difference as compared to the control (PBS) group. Data were obtained from
3 independent experiments, bars in the figures represent mean ± SEM.
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3.12.

MnTE-2-PyP mediated reduction in KEAP1 levels (canonical) precedes

changes in SQSTM1 (non-canonical)

To understand the mechanism of NRF2 pathway activation by MnTE-2-PyP treatment, we
investigated changes in the canonical NRF2 signaling pathway involving KEAP1 and noncanonical NRF2 signaling pathway involving SQSTM1 Ser349 phosphorylation. We
performed immunoblotting time course experiments with MnTE-2-PyP treatment and
looked at the changes in NRF2, KEAP1, SQSTM1, p-SQSTM1 (Ser349) and NQO1 levels.
An increase in NRF2 levels upon MnTE-2-PyP treatment showed significant differences
at the 24 hour time point (Fig. 14: A-B). KEAP1 levels begin to significantly decrease
(~0.49-fold) at the 6 hour time point and reach a maximum decrease around the 48 hour
time point (~0.36-fold) (Fig. 14: A, C). Whereas, a significant increase in SQSTM1 levels
and phosphorylation of SQSTM1 (Ser349) begin around the 48 hour time point (Fig. 14:
A, D-E). Thereby, indicating that changes in the canonical NRF2 signaling pathway
precede changes in the non-canonical NRF2 signaling pathway with MnTE-2-PyP
treatment.
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Figure 14. MnTE-2-PyP mediated reduction in KEAP1 levels (canonical) precedes
changes in SQSTM1 (non-canonical). (A) Immunoblotting time course analysis of
NRF2, KEAP1, SQSTM1, phospho-SQSTM1 (p-SQSTM1 Ser349), and NQO1 protein
level after MnTE-2-PyP treatment of P3158 cells. (B) Quantification of NRF2 levels
from immunoblot in panel A. (C) Quantification of KEAP1 levels from immunoblot in
panel A. (D) Quantification of SQSTM1 levels from immunoblot in panel A. (E)
Quantification of p-SQSTM1/SQSTM1 levels from immunoblot in panel A. Differences
were determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for
multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p <
0.00005) denotes a significant and the symbol (ns) denotes a non-significant difference
as compared to the control (PBS) group. Data for figures in panel A-C were obtained
from 3 independent experiments, bars in the figures represent mean ± SEM.
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3.13.

Changes in SQSTM1 occurs after NRF2 pathway activation by MnTE-2-PyP

To test if SQSTM1 is involved in NRF2 activation in human prostate fibroblast cells upon
MnTE-2-PyP treatment, we downregulated SQSTM1 and immunoblotted for NRF2, NQO1
and KEAP1. We also downregulated NRF2 and NQO1 using siRNA molecules in the same
experiment to serve as controls. We observed that the knockdown of SQSTM1 did not
prevent the activation of NRF2 by MnTE-2-PyP (lane 3-4, Fig. 15: A). Further, knockdown
of NRF2 prevented an increase in SQSTM1 levels upon MnTE-2-PyP treatment (lane 56, Fig. 15: A). The knockdown of NQO1 did not prevent changes in either NRF2 or
SQSTM1 levels caused by MnTE-2-PyP treatment (lane 7-8, Fig. 15: A). This data
indicates that changes in SQSTM1 are a downstream consequence of activation of the
NRF2 signaling pathway.
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Figure 15. Changes in SQSTM1 occurs after NRF2 pathway activation by MnTE2-PyP. (A) Immunoblotting results of Scrambled siRNA (Scr), SQSTM1 siRNA
(Sqstm1), NRF2 siRNA (Nrf2) and Nqo1 (siRNA) treated with or without MnTE-2-PyP
(4 days). Relative quantification of each protein band is enumerated below each
immunoblot. Data in panel A are representative of 3 independent experiments.
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3.14.

MnTE-2-PyP treatment does not activate NRF2 signaling in KEAP1 knockout

mouse embryonic fibroblast cells

To confirm the role of KEAP1 in the activation of the NRF2 signaling pathway by MnTE2-PyP treatment, we used KEAP1 knockout and wild-type mouse embryonic fibroblast
cells. In KEAP1 knockout cells, we did not observe an increase in nuclear NRF2 levels
(lane 3-4, Fig. 16: A) or an increase in NQO1 levels caused by MnTE-2-PyP treatment
(lane 7-8, Fig. 16: A). Further, the increase in SOD2 levels caused by MnTE-2-PyP
treatment was partially prevented in KEAP1 knockout cells (lane 5-8, Fig. 16: A). This data
indicates that MnTE-2-PyP is acting on KEAP1 to activate the NRF2 signaling pathway.
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Figure 16. MnTE-2-PyP treatment does not activate NRF2 signaling in KEAP1
knockout mouse embryonic fibroblast cells. (A) Immunoblotting analysis of nuclear
and cytoplasmic extracts from wild type (W.T.) and KEAP1 knockout (K.O.) mouse
embryonic fibroblast cells treated with MnTE-2-PyP for 5 days. Relative quantification
of each protein band is enumerated below each immunoblot. Data in panel A are
representative of 3 independent experiments.
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3.15.

MnTE-2-PyP treatment leads to an increase in hydrogen peroxide levels

MnTE-2-PyP, a superoxide scavenger, converts superoxide molecules to hydrogen
peroxide. We hypothesized that hydrogen peroxide generated by MnTE-2-PyP could play
a role in NRF2 pathway activation. To understand and quantify the changes in hydrogen
peroxide upon MnTE-2-PyP treatment, we used the ROS-GLO H2O2 assay. We observed
a significant increase in hydrogen peroxide levels within 3 hours of MnTE-2-PyP treatment
in human prostate fibroblast cells (Fig. 17: A). A maximum increase in hydrogen peroxide
levels can be observed at the 6 hour time point of MnTE-2-PyP treatment (Fig. 17: A).
Beyond the 6-hour time point, the hydrogen peroxide levels are significantly higher but
reduced, likely due to the activation of the NRF2 signaling pathway, which leads to an
increase in the expression of hydrogen peroxide scavenging enzymes or a decrease in
cell proliferation upon MnTE-2-PyP treatment. This data indicates that the increase in
hydrogen peroxide caused by MnTE-2-PyP treatment may be responsible for the
activation of the NRF2 signaling pathway through KEAP1.
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Figure 17. MnTE-2-PyP treatment leads to an increase in hydrogen peroxide
levels. (A) Hydrogen peroxide generation by MnTE-2-PyP treatment over time in HPrF
cells, measured by ROS-GLO H2O2 assay. Differences were determined by using a 1way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol
(**p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant and the symbol (ns)
denotes a non-significant difference as compared to the control (PBS) group. Data
were obtained from 3 independent experiments, bars in the figures represent mean
± SEM.
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3.16.

Hydrogen peroxide treatment activates the NRF2 signaling pathway

Hydrogen peroxide can act as a signaling molecule, which can lead to either activation or
inhibition of signaling pathways that contain redox-sensitive thiols [195]. To further
understand the mechanism of NRF2 signaling pathway activation by MnTE-2-PyP, we
treated human primary fibroblast (HPrF) cells with hydrogen peroxide. We used HPrF cells
as they are more sensitive to changes in signaling pathways and serve as an additional
cell type to confirm NRF2 pathway activation. We treated HPrF cells with 25 µM, 50 µM,
and 100 µM of hydrogen peroxide every 24 hours for four consecutive days. With
increasing doses of hydrogen peroxide, we observed a ~1.7-2.9-fold significant increase
in NRF2 levels (Fig. 18: A-B). We also observed significant increases in NQO1 (~2.5-fold)
and SOD2 (~2.8) levels with the addition of hydrogen peroxide at the highest dose (100
µM, Fig. 18: A, C-D). This indicates that the conversion of superoxide to hydrogen
peroxide by MnTE-2-PyP could be responsible for NRF2 pathway activation.
.
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Figure 18. Hydrogen peroxide treatment activates the NRF2 signaling pathway.
(A) Immunoblotting analysis of NRF2, NQO1 and SOD2 expression in HPrF cells
treated with hydrogen peroxide (25 μM, 50 μM, and 100 μM) every day for 4
consecutive days. (B) Quantification of NRF2 levels from immunoblot in panel A. (C)
Quantification of NQO1 levels from immunoblot in panel A. (D) Quantification of SOD2
levels from immunoblot in panel A. Differences were determined by using a 1-way
ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol (**p
< 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant and the symbol (ns)
denotes a non-significant difference as compared to the control (PBS) group. Data
were obtained from 3 independent experiments, bars in the figures represent mean
± SEM.
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3.17.

Removal of hydrogen peroxide using N-acetyl cysteine (NAC) treatment

prevents NRF2 pathway activation by MnTE-2-PyP treatment

To remove hydrogen peroxide from cells and test its role in the activation of the NRF2
pathway in prostate fibroblast cells, we used N-acetyl cysteine (NAC), which is a precursor
for glutathione production (hydrogen peroxide scavenger). We pretreated HPrF cells with
NAC for two days with a 12-hour replenishment cycle and then treated with MnTE-2PyP
for three days and measured changes in the NRF2 pathway. We observed that a dosedependent NAC (1 mM and 2 mM) treatment caused a decrease in NRF2 levels (~0.5fold), and MnTE-2-PyP failed to significantly increase NRF2 levels upon NAC treatment
(Fig. 19: A-B). Further, we observed that there was no significant increase in either NQO1
or SOD2 levels in NAC + MnTE-2-PyP treated groups (Fig. 19: A, C-D), indicating that the
hydrogen peroxide generated by MnTE-2-PyP is likely playing a role in NRF2 pathway
activation by oxidizing KEAP1, leading to a reduction in KEAP1-NRF2 interaction.
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Figure 19. Removal of hydrogen peroxide using N-acetyl cysteine (NAC)
treatment prevents NRF2 pathway activation by MnTE-2-PyP treatment. (A)
Immunoblotting analysis of HPrF cells pretreated for 2 days (every 12 hours) with NAC
(1 mM and 2 mM) followed by MnTE-2-PyP treatment for 3 days. (B) Quantification of
NRF2 levels from immunoblot in panel A. (C) Quantification of NQO1 levels from
immunoblot in panel A. (D) Quantification of SOD2 levels from immunoblot in panel A.
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s
test for multiple comparisons. The symbol (*p < 0.05, **p < 0.005) denotes a significant
and the symbol (ns) denotes a non-significant difference as compared to the control
(PBS) group. Data were obtained from 3 independent experiments, bars in the figures
represent mean ± SEM.
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3.18.

MnTE-2-PyP treatment increased NAD+ and NADH levels

An increase in NRF2 signaling and the downstream target NQO1 can lead to significant
changes in cellular metabolites. NQO1 is an enzyme that is involved in the conversion of
quinones to hydroquinones and utilizes NADH for this conversion [237, 238]. Thus, when
NQO1 detoxifies quinones, it produces NAD+ [239, 240], which is also a cofactor for the
activity of sirtuin enzymes that play a significant role in cellular protection through the
regulation of acetylation of histones and non-histone proteins [237, 239-243]. Therefore,
we measured the levels of NAD+ and NADH after MnTE-2-PyP treatment in prostate
fibroblast cells (P3158). We found a significant ~2-fold increase in NAD+ and NADH levels
(Fig. 20: A, B). The ratio of NAD+/NADH did not change significantly; this is an indicator
that the redox health of the cells post MnTE-2-PyP treatment is maintained (Fig. 20: C).
Similarly, in primary human prostate fibroblast (HPrF) cells, we observed a significant
increase in NAD+ and NADH levels after MnTE-2-PyP treatment and radiation exposure
(Fig. 20: D, E). In HPrF cells, the ratio of NAD+/NADH showed a significant decrease in
the samples exposed to radiation, and MnTE-2-PyP treatment prevented this decrease in
NAD+/NADH ratio in comparison to the PBS treated group (Fig. 20: F). This data indicates
that changes in the NRF2 signaling pathway due to MnTE-2-PyP treatment can impact
cellular metabolites such as NAD+ and NADH.
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Figure 20. MnTE-2-PyP treatment increased NAD+ and NADH levels. P3158 cells
and HPrF cells were pretreated with MnTE-2-PyP for 24 hours and then analyzed 48
hours post-irradiation. (A) Relative NAD+ levels in P3158 cells. (B) Relative NADH
levels in P3158 cells. (C) Relative ratios of NAD+/NADH levels in P3158 cells. (D)
Relative NAD+ levels in HPrF cells. (E) Relative NADH levels in HPrF cells. (F) Relative
ratios of NAD+/NADH levels in HPrF cells. Differences were determined by using a 1way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol
(*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant and the
symbol (ns) denotes a non-significant difference as compared to the control (PBS)
group. Data were obtained from 3 independent experiments, bars in the figures
represent mean ± SEM.
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3.19.

MnTE-2-PyP treatment increased the activity of sirtuin family proteins in

nuclear and mitochondrial extracts

To further understand the impact of an increase in NAD+ levels by MnTE-2-PyP treatment
on the activity of radioprotective enzymes, we measured the activity of the sirtuin family of
proteins that use NAD+ as a cofactor for its activity. Sirtuins are a class of proteins that
possess deacetylase activity or mono-ribosyltransferase activity and are associated with
epigenetic remodeling, cellular protection, radiation protection, sugar metabolism, and cell
cycle regulation [243, 244]. Sirtuins localized in different subcellular organelles, such as
the nucleus and mitochondria, play an important role in the development of RIF [56, 244].
Therefore, we measured sirtuin activity in nuclear extracts and found a ~1.4-1.8-fold
increase in sirtuin activity in MnTE-2-PyP treated groups (Fig. 21: A). Radiation exposure
also led to a ~1.4-fold increase in sirtuin activity. However, maximum change (~1.8-fold)
in nuclear sirtuin activity was observed in MnTE-2-PyP treated group exposed to radiation
(Fig. 21: A). In mitochondrial extracts, we observed a significant ~1.5-fold increase in
sirtuin activity in the MnTE-2-PyP treated groups (Fig. 21: B). There was no significant
increase in mitochondrial sirtuin activity after radiation exposure, which may be a reason
for an increase in mitochondrial damage and a rise in mitochondrial ROS levels postirradiation [245-247]. This data indicates that MnTE-2-PyP treatment causes an increase
in sirtuin activity in nuclear and mitochondrial extracts.
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Figure 21. MnTE-2-PyP treatment increased the activity of sirtuin family proteins
in nuclear and mitochondrial extracts. (A) Relative sirtuin activity in nuclear extracts
of P3158 cells. (B) Relative sirtuin activity in mitochondrial extracts of P3158 cells.
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s
test for multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p
< 0.00005) denotes a significant and the symbol (ns) denotes a non-significant
difference as compared to the control (PBS) group. Data were obtained from 3
independent experiments, bars in the figures represent mean ± SEM.
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3.20.

MnTE-2-PyP treatment increased SOD2 levels, SOD2 deacetylation (Ac-

K122) and SOD2 activity

Since we observed an increase in mitochondrial sirtuin activity after MnTE-2-PyP
treatment, we investigated the acetylation status of mitochondrial proteins. SOD2, is a
downstream target of SIRT3 (mitochondrial sirtuin). SIRT3 is known to directly deacetylate
SOD2, which is the primary mitochondrial superoxide scavenging enzyme, and its
acetylation status influences its activity. Therefore, we investigated the acetylation of
SOD2 at K68 and K122 residues that can affect SOD activity [248-250]. SOD2 K68
acetylation directs its homotetramer complex formation [251], and SOD2 K122
deacetylation increases its catalytic activity by maintaining the positive charge of the
electrostatic funnel that directs the movement of superoxide molecules to the active site
of SOD2 [252]. Further, SOD2 expression is controlled by NRF2 activity, and we have
observed a ~1.5-fold significant increase in SOD2 levels in MnTE-2-PyP treated groups
(Fig. 22: A-B). We did not observe a significant increase in SIRT3 levels in MnTE-2-PyP
treated groups (Fig. 22: A, C). However, MnTE-2-PyP treatment decreased SOD2
acetylation at K122 residue (~0.41-fold) but did not change acetylation at K68 in
comparison to PBS treated group normalized to total SOD2 levels (Fig. 22: A, D-E). We
also observed a 1.52-fold significant increase in SOD2 K122 acetylation after radiation
exposure, which was not observed in MnTE-2-PyP + radiated group (Fig. 22: A, E). This
decrease in acetylation of SOD2 at K122 residue also correlated with a ~1.5-fold
significant increase in SOD2 activity using an in-gel assay (Fig. 22: A, F). An increase in
SOD2 activity can also be attributed to an increase in total SOD2 protein levels in
comparison to PBS treated groups. Since SOD2 is a mitochondrial protein, we isolated
the mitochondria from P3158 cells and measured SOD activity by a more sensitive
xanthine oxidase - SOD activity assay. We again observed a significant increase in SOD
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activity in mitochondrial extracts of MnTE-2-PyP treated groups (Fig. 22: G). Notably, this
increase in mitochondrial SOD activity could be responsible for the long-term indirect
superoxide scavenging capacity induced by MnTE-2-PyP. Further, this increase in
superoxide scavenging capacity in the mitochondria by SOD2 can be crucial in
maintaining mitochondrial functioning post-irradiation [245, 253].
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Figure 22. MnTE-2-PyP treatment increased SOD2 levels, SOD2 deacetylation
(Ac-K122) and SOD2 activity. P3158 cells were pretreated with MnTE-2-PyP for 24
hours and then analyzed 4 days post-irradiation exposure (5 Gy). (A) Immunoblotting
analysis of NRF2, NQO1, total SOD2, SIRT3, SOD2 Ac-K68, SOD2 Ac-K122, and ingel SOD2 activity assay from whole-cell lysate. (B) Quantification of total SOD2 levels
from immunoblot in panel A. (C) Quantification of SIRT3 levels from immunoblot in
panel A. (D) Quantification of SOD2 acetylation at K68 to total SOD2 levels from
immunoblot in panel A. (E) Quantification of SOD2 acetylation at K122 to total SOD2
levels from immunoblot in panel A. (F) Quantification of SOD2 activity by in-gel assay
shown in panel A. (G) Quantification of SOD activity (% inhibition rate) in the
mitochondrial extracts using the xanthine oxidase - SOD activity assay. Differences
were determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for
multiple comparisons. The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005) denotes a
significant and the symbol (ns) denotes a non-significant difference as compared to the
control (PBS) group. Data were obtained from 3 independent experiments, bars in the
figures represent mean ± SEM.
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3.21.

NRF2 downregulation increases α-SMA levels (myofibroblast marker) which

is partially rescued by MnTE-2-PyP treatment

Radiation-induced fibrosis develops due to the transformation of fibroblasts to
myofibroblasts, which are also known as activated fibroblasts. Identification and inhibition
of pathways responsible for this transformation can prevent the development of fibrosis.
An active NRF2 pathway prevents fibroblast transformation due to a reduction in the levels
of ROS and the inhibition of the TGF-β signaling pathway, which is a known pro-fibrotic
pathway. Further, we hypothesized that enhanced NRF2 signaling activity upon MnTE-2PyP treatment assists in maintaining normal fibroblast phenotype. HPrF cell are more
sensitive to fibroblast to myofibroblast transformation in comparison to the immortalized
prostate fibroblast cells (P3158). Therefore, we investigated the formation of the
myofibroblast phenotype using HPrF cells. To study the role of ROS-mediated
myofibroblasts formation, we seeded HPrF cells in the presence of NRF2 siRNA and
MnTE-2-PyP treatment at the same time (day 0). After five days of treatment, cells were
collected and analyzed for myofibroblast phenotype by measuring alpha-smooth muscle
actin (α-SMA) levels, changes in cell size, and collagen contraction (Fig. 23-25). Further,
we looked at differences in superoxide and total reactive oxygen species levels (Fig. 26).
NRF2 protein is maintained at homeostatic levels by the binding of NRF2 to KEAP1 for
immediate adaptive cellular responses in the face of a changing microenvironment. The
use of NRF2 siRNA in experiments does not affect the NRF2 protein levels immediately,
and it requires 48-72 hours for NRF2 protein to be fully reduced. Whereas, MnTE-2-PyP
treatment effects the NRF2-KEAP1 system within the 48 hours of treatment. Therefore,
the addition of NRF2 siRNA and MnTE-2-PyP at the same starting time point can still lead
to partial NRF2 signaling pathway activation. In immunoblotting experiments setup
according to the experimental timeline showed in Fig. 23: A, we observed that only a partial
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NRF2 knockdown was achieved in the group treated with NRF2 siRNA and MnTE-2-PyP
in comparison to the NRF2 siRNA treated group (Fig. 23: B). This also led to a partial
expression of NQO1 in the NRF2 siRNA + MnTE-2-PyP treatment group (Fig. 23: B). αSMA levels, a marker for myofibroblast phenotype, increased by ~2.5-fold, when we
compared the NRF2 siRNA + PBS treated group to the Scr siRNA + PBS treated group
(Fig. 23: B, C). We observed a ~2.0-fold significant increase in α-SMA levels in the NRF2
siRNA + MnTE-2-PyP treated group when compared to Scr siRNA + PBS treated group,
likely due to the partial loss of NRF2 in the NRF2 siRNA + MnTE-2-PyP treated group
(Fig. 23: B, C). However, the α-SMA levels in the NRF2 siRNA + MnTE-2-PyP treatment
group were significantly lower than the NRF2 siRNA + PBS treatment group (Fig. 23: B,
C). This indicated that a partial rescue in myofibroblast phenotype could be achieved due
to partial activation of NRF2 by MnTE-2-PyP in the NRF2 siRNA + MnTE-2-PyP treatment
group.
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Figure 23. NRF2 downregulation increases α-SMA levels (myofibroblast marker)
which is partially rescued by MnTE-2-PyP treatment. (A) Experimental timeline for
siRNA treatment (Scrambled-Scr and NRF2 siRNA) and MnTE-2-PyP treatment. (B)
Immunoblotting analysis of NRF2, NQO1, and α-SMA expression. (C) Quantification of
α-SMA levels (myofibroblast marker) from immunoblot in panel B. Differences were
determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple
comparisons. The symbol (**p < 0.005, ****p < 0.00005) denotes a significant and the
symbol (ns) denotes a non-significant difference as compared to the control (PBS)
group. Data were obtained from 3 independent experiments, bars in the figures
represent mean ± SEM.
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3.22.

NRF2 downregulation increases cell size, which is rescued by MnTE-2-PyP

treatment due to partial NRF2 activation

Activated fibroblasts or myofibroblasts are larger in size as compared to normal
fibroblasts. In the same experimental setup and timeline as in (Fig. 24: A), we measured
changes in cell size to determine the myofibroblast phenotype. NRF2 knockdown caused
a ~3-fold significant increase in cell size, which was significantly reduced by MnTE-2-PyP
treatment to ~1.4-fold a significant increase in the NRF2 knockdown group (Fig. 24: A-B).
This indicates that MnTE-2-PyP can prevent changes in cell size or myofibroblast
phenotype when there is partial NRF2 activation.
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Figure 24. NRF2 downregulation increases cell size, which is rescued by MnTE2-PyP treatment due to partial NRF2 activation. (A) Representative images of
changes in cell morphology (HPrF cells) from Scr siRNA, NRF2 siRNA and MnTE-2PyP treated groups. Scale bar: 250 μm. (B) Quantification of cell size by measuring the
area of each cell after tracing cell boundary using ImageJ. Differences were determined
by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple comparisons.
The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant
and the symbol (ns) denotes a non-significant difference as compared to the control
(PBS) group. Data were obtained from 3 independent experiments, bars in the figures
represent mean ± SEM.
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3.23.

NRF2 downregulation activates fibroblast cells, which is rescued by MnTE-

2-PyP treatment due to partial NRF2 activation

To further measure the myofibroblast phenotype, the most widely accepted technique is
the collagen contraction assay, where the ability of cells to contract collagen discs is
measured. The increase in contractility by myofibroblast cells is due to an increase in the
expression of α-SMA. Upon NRF2 knockdown by siRNA, a significant (p=0.0004) increase
in collagen contraction was observed in the PBS treated group (Fig. 25: A-B). In the MnTE2-PyP treated group, with partial NRF2 knockdown, the collagen contraction is prevented
in comparison to the NRF2 knockdown + PBS treated group (Fig. 25: A-B). This data
indicates that an active NRF2 pathway is essential to prevent the formation of
myofibroblast cells from primary prostate human fibroblast cells.
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Figure 25. NRF2 downregulation activates fibroblast cells, which is rescued by
MnTE-2-PyP treatment due to partial NRF2 activation. (A) Representative collagen
contraction assay to measure activation of fibroblast cells (HPrF cells) from Scr siRNA,
NRF2 siRNA and MnTE-2-PyP treated groups. (B) Quantification of collagen disc area
from panel A as measured using ImageJ. Differences were determined by using a 1way ANOVA followed by a post hoc Tukey’s test for multiple comparisons. The symbol
(*p < 0.05, ***p < 0.0005) denotes a significant and the symbol (ns) denotes a nonsignificant difference as compared to the control (PBS) group. Data were obtained from
3 independent experiments, bars in the figures represent mean ± SEM.
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3.24.

NRF2 downregulation increases superoxide and total ROS levels, and MnTE-

2-PyP treatment reduces superoxide and total ROS levels in HPrF cells

The NRF2 signaling pathway is the major antioxidant pathway in different cell types. Loss
of the NRF2 pathway can lead to an increase in reactive oxygen species (ROS) that can
drive fibroblast to myofibroblast transformation. Therefore, we investigated the changes in
superoxide and total ROS levels by DHE assay. In the same experimental setup and
timeline, as shown in Fig. 23: A, the highest levels of superoxide (1.50-fold) and total ROS
(1.45-fold) were found in the NRF2 knockdown group treated with PBS (Fig. 26: A). In
MnTE-2-PyP treated group, both superoxide and total ROS were significantly reduced
(Fig. 26: A). In MnTE-2-PyP treated group with NRF2 knockdown, the superoxide and total
ROS were significantly lower than the corresponding PBS treated NRF2 knockdown group
due partial NRF2 activity (Fig. 26: B). This indicates that MnTE-2-PyP likely scavenges
through both an NRF2 dependent and independent mechanism.
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Figure 26. NRF2 downregulation increases superoxide and total ROS levels, and
MnTE-2-PyP treatment reduces superoxide and total ROS levels in HPrF cells.
(A) DHE assay used to measure superoxide levels by flow cytometric analysis (405
nm). (B) DHE assay used to measure total ROS by flow cytometric analysis (488 nm).
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s
test for multiple comparisons. The symbol (**p < 0.005, ***p < 0.0005, ****p < 0.00005)
denotes a significant and the symbol (ns) denotes a non-significant difference as
compared to the control (PBS) group. Data were obtained from 3 independent
experiments, bars in the figures represent mean ± SEM.
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3.25.

MnTE-2-PyP cannot prevent an increase in the α-SMA levels post-irradiation

in the absence of the NRF2 pathway

To investigate the role of NRF2 in the context of radiation exposure (3 Gy) and to achieve
a complete NRF2 knockdown in MnTE-2PyP treated groups, we changed the
experimental timeline for siRNA treatment and MnTE-2-PyP treatment as shown in (Fig.
27: A). We seeded the cells with siRNA, and after two days, we treated the cells with
MnTE-2-PyP, to eliminate any NRF2 protein that could be activated post-translationally by
MnTE-2-PyP treatment. After 6 hours of MnTE-2-PyP treatment, we exposed the cells to
radiation and performed immunoblotting on day 5 to confirm changes in NRF2 levels and
its downstream target, NQO1 (Fig. 27: B-C). There was a significant increase in NRF2
levels in the scrambled siRNA groups treated with MnTE-2-PyP but there was no
significant increase in NRF2 levels in NRF2 siRNA groups treated with MnTE-2-PyP (Fig.
27: B-C). In line with this, NQO1 levels were increased in scrambled siRNA groups treated
with MnTE-2-PyP and completely lost in all NRF2 siRNA groups (Fig. 27: B). A significant
increase in α-SMA levels were observed in scrambled siRNA treated, radiation-exposed
PBS group, and all the NRF2 knockdown groups (Fig. 27: B, D). The maximum increase
in α-SMA levels (>2-fold) can be observed in the NRF2 knockdown groups (Fig. 27: B, D).
MnTE-2-PyP treatment reduced α-SMA levels in the scrambled treated, radiation exposed
group but failed to significantly reduce α-SMA levels in NRF2 knockdown groups (Fig. 27:
B, D). This data indicates that MnTE-2-PyP cannot prevent the increase in α-SMA levels
post-irradiation in the absence of the NRF2 pathway.
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Figure 27. MnTE-2-PyP cannot prevent the increase in α-SMA levels postirradiation in the absence of NRF2 pathway. (A) Experimental timeline for siRNA
treatment (Scr siRNA and NRF2 siRNA), MnTE-2-PyP treatment, and radiation
exposure (3 Gy) in HPrF cells. (B) Immunoblotting analysis of NRF2, NQO1, and αSMA expression. (C) Quantification of NRF2 from panel B after siRNA mediated
knockdown. (D) Quantification of α-SMA from panel B, a marker for myofibroblast cells.
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s
test for multiple comparisons. The symbol (**p < 0.005, ****p < 0.00005) denotes a
significant and the symbol (ns) denotes a non-significant difference as compared to the
control (PBS) group. Data were obtained from 3 independent experiments, bars in the
figures represent mean ± SEM.
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3.26.

MnTE-2-PyP treatment cannot prevent myofibroblast formation post-

irradiation in the absence of the NRF2 pathway

To further measure the myofibroblast phenotype, we performed the collagen contraction
assay with the experimental timeline shown in Fig. 27: A. MnTE-2-PyP prevents increase
in α-SMA levels and the contraction of collagen discs in the scrambled treated + radiation
exposed group, but failed to significantly rescue myofibroblast formation in the NRF2
knockdown groups (Fig. 28: A-B). This indicates that the NRF2 pathway is essential to
prevent myofibroblast formation and that MnTE-2-PyP prevents radiation-induced
myofibroblast formation, at least in part, through the activation of the NRF2 pathway.
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Figure 28. MnTE-2-PyP treatment cannot prevent myofibroblast formation postirradiation in the absence of NRF2 pathway. (A) Representative collagen contraction
assay to measure myofibroblast phenotype formation after siRNA treatment (Scr siRNA
and NRF2 siRNA), MnTE-2-PyP treatment, and radiation exposure (3 Gy) in HPrF cells.
(B) Quantification of collagen disc area from panel A measured using ImageJ.
Differences were determined by using a 1-way ANOVA followed by a post hoc Tukey’s
test for multiple comparisons. The symbol (**p < 0.005, ***p < 0.0005, ****p < 0.00005)
denotes a significant and the symbol (ns) denotes a non-significant difference as
compared to the control (PBS) group. Data were obtained from 3 independent
experiments, bars in the figures represent mean ± SEM.
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3.27.

Prostate fibroblasts from NRF2-/- mice do not undergo transformation to

myofibroblasts post-irradiation

NRF2-/- mice have been shown to be sensitive and resistant to radiation damage
depending on the tissue under investigation. Therefore, to test the role of NRF2 pathway
activation by MnTE-2-PyP in prostate tissue, we isolated primary mouse prostate
fibroblast (MPF) cells from Nfe2l2tm1Ywk (NRF2) knockout mice (C57BL/6J) obtained from
The Jackson Laboratory. We cultured these cells ex vivo to investigate the role of MnTE2-PyP in radioprotection. We noticed that these fibroblasts were slower growing, were
dependent on cell-cell contact for survival, and more challenging to culture in vitro in
comparison to wild type primary mouse prostate fibroblast cells. Upon subjecting the
NRF2-/- MPF cells to 24 hours of MnTE-2-PyP treatment and 2 Gy radiation exposure, no
stark visual changes in cellular morphology can be observed at day five post-irradiation
(data not shown). The collagen contraction assay showed no differences in irradiated cells
with or without MnTE-2-PyP treatment (Fig. 29: A-B). Therefore, the NRF2-/- MPF cells
appear to be activated without radiation exposure, and the role of MnTE-2-PyP in
radioprotection cannot be investigated in these cells ex vivo (Fig. 29: A-B).
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Figure 29. Prostate fibroblasts from NRF2-/- mice do not undergo transformation
to myofibroblasts post-irradiation. (A) Representative collagen contraction assay to
measure fibroblast activation isolated from NRF2-/- (NRF2 knockout) mice, exposed to
MnTE-2-PyP treatment and radiation exposure (2 Gy). (B) Quantification of collagen
disc area from panel A as measured by using ImageJ. Differences were determined by
using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple comparisons.
The symbol (ns) denotes a non-significant difference as compared to the control (PBS)
group. Data were obtained from 3 independent experiments, bars in the figures
represent mean ± SEM.
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3.28.

Mitochondrial function assayed by measuring the flow of electrons into the

electron transport chain, post-irradiation, and MnTE-2-PyP treatment

Mitochondria are vital energy-producing cellular organelles that are damaged due to
radiation exposure and contribute to the increase in ROS, which drives fibroblast to
myofibroblast transformation. MnTE-2-PyP could protect the mitochondria from radiation
damage and can improve mitochondrial functioning due to the removal of superoxide and
the activation of the NRF2 signaling pathway. To test mitochondrial functioning postirradiation and MnTE-2-PyP treatment, we used Biolog’s Mitoplate S1 assay that has 30
preloaded substrates used by the mitochondria in 96 well plates. Mitochondrial function is
assayed by measuring the rates of electron flow into and through the electron transport
chain (ETC) from metabolic substrates that produce NAD(P)H or FADH2 such as L-malate,
succinate, and pyruvate. Each substrate follows a different route, using different
transporters to enter the mitochondria and different dehydrogenases to produce NAD(P)H
or FADH2, The electrons travel from the beginning (1 or 2) to the distal portion of the
electron transport chain where a tetrazolium redox dye acts as a terminal electron
acceptor that turns purple upon reduction.
We used human prostate fibroblast (P3158) cells, exposed to radiation (3 Gy) ± PBS or
MnTE-2-PyP treatment, to study mitochondrial functioning. Upon radiation exposure, in
the absence of any of the 30 substrates, there is an increase in the NAD(P)H/FADH2
production leading to an increase in electron flow into and through the ETC in comparison
to the PBS treated samples (Fig. 30: A). There is no significant difference between the
PBS + radiation treated samples and the MnTE-2-PyP + radiation treated samples (Fig.
30: A). Significant differences were observed in the PBS + radiation treated samples and
the MnTE-2-PyP + radiation treated samples, when incubated with Pyruvic acid (Fig. 30:
I), D,L-Iscocitric acid (Fig. 30: M), Succinic acid (Fig. 30: P), Fumaric acid (Fig. 30: Q),
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Tryptamine (Fig. 30: AA) and L-Ornithine (Fig. 30: AC). There was no significant difference
between the PBS + radiation treated samples and the MnTE-2-PyP + radiation treated
samples, when incubated with α-D-Glucose (Fig. 30: B), D-Glucose-6-PO4 (Fig. 30: C), DGluconate-6-PO4 (Fig. 30: D), Alanyl-Glutamine (Fig. 30: E), Glycogen (Fig. 30: F), DGlucose-1-PO4 (Fig. 30: G), D,L-α-Glycerol-PO4 (Fig. 30: H), L-Lactic acid (Fig. 30: J),
Citric acid (Fig. 30: K), cis-Aconitic acid (Fig. 30: L), α-Keto-Glutaric acid (Fig. 30: N), LGlutamic acid (Fig. 30: O), L-Malic acid (Fig. 30: R), γ-Amino-Butyric acid (Fig. 30: S), D,Lβ- Hydroxy-Butyric acid (Fig. 30: T), α-Keto-Butyric acid (Fig. 30: U), Acetyl-L-Carnitine
(Fig. 30: V), Palmitoyl-D,L-Carnitine (Fig. 30: W), Octanoyl-L-Carnitine (Fig. 30: X), LLeucine (Fig. 30: Y), α-Keto-Isocaproic Acid (Fig. 30: Z) and L-Serine (Fig. 30: AB).
Further, there is no significant difference in Pyruvic acid (Fig. 30: I), D,L-Iscocitric acid
(Fig. 30: M), Succinic acid (Fig. 30: P), Fumaric acid (Fig. 30: Q), α-Keto-Glutaric acid (Fig.
30: N) and L-Malic acid (Fig. 30: R) utilization when we compare the PBS treated sample
to the MnTE-2-PyP + radiation treated sample. First, this data indicates MnTE-2-PyP
treatment could be involved in protecting the mitochondria against radiation damage,
thereby reducing its dependence on or consumption of these substrates (Pyruvic acid, D,
L-Iscocitric acid, α-Keto-Glutaric acid, Succinic acid, Fumaric acid, L-Malic acid,
Tryptamine, and L-Ornithine). Second, reduction in utilization of these substrates upon
MnTE-2-PyP treatment could be an indicator of enhanced activity of the enzymes involved
in cellular or mitochondrial metabolism. We think MnTE-2-PyP treatment could be
effecting glycolysis (Pyruvic acid), citric acid cycle or Krebs cycle (Pyruvic acid, D, LIscocitric acid, α-Keto-Glutaric acid, Succinic acid, Fumaric acid, L-Malic acid), tryptamine
metabolism (Tryptamine) and urea cycle or ornithine cycle (L-Ornithine). Conversely,
radiation exposure leads to an increase in the utilization of mitochondrial substrates to
either increase the energy output of the cells or repair cellular damage.
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Figure 30. Mitochondrial function assayed by measuring the flow of electrons
into the electron transport chain, post-radiation and MnTE-2-PyP treatment.
P3158 cells were exposed to radiation (3 Gy) and pretreated with MnTE-2-PyP. Data
collected at the 120 min after addition of cells to each well. Relative electron flow in the
presence of (A) No substrate (Control), (B) α-D-Glucose, (C) D-Glucose-6-PO4, (D) DGluconate-6-PO4, (E) Alanyl-Glutamine, (F) Glycogen, (G) D-Glucose-1-PO4, (H) D,Lα-Glycerol-PO4, (I) Pyruvic Acid, (J) L-Lactic Acid, (K) Citric Acid, (L) cis-Aconitic Acid,
(M) D,L-Isocitric Acid, (N) α-Keto-Glutaric Acid, (O) L-Glutamic Acid, (P) Succinic Acid,
(Q) Fumaric Acid, (R) L-Malic Acid, (S) γ-Amino-Butyric Acid, (T) D,L-β- HydroxyButyric Acid, (U) α-Keto-Butyric Acid, (V) Acetyl-L-Carnitine, (W) Palmitoyl-D,LCarnitine, (X) Octanoyl-L-Carnitine, (Y) L-Leucine, (Z) α-Keto-Isocaproic Acid, (AA)
Tryptamine, (AB) L-Serine, and (AC) L-Ornithine. Differences were determined by
using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple comparisons.
The symbol (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005) denotes a significant
and the symbol (ns) denotes a non significant difference as compared to the control
(PBS) group. Data were obtained from 3 independent experiments, bars in the figures
represent mean ± SEM.
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3.29.

Time dependent, MnTE-2-PyP mediated activation of 16 oxidative stress

related transcription factors

Hydrogen peroxide is a ROS that is less reactive than superoxide but can still oxidize and
cause changes in signaling pathways through post-translational modifications of cysteine
residues. We know that MnTE-2-PyP converts superoxide to hydrogen peroxide, which
leads to activation of the NRF2 signaling pathway in prostate fibroblast cell. However, we
do not know the effect of MnTE-2-PyP on other oxidative stress sensitive transcription
factors that may be activated along with NRF2. To study the changes in other transcription
factors, we used Signosis’s oxidative stress TF activation profiling plate array, that
measures changes in 16 oxidative stress related TFs, including AP1, ATF4, CBF/NFY,
EGR1, ETS, FOXO1, HIF, HSF, IRF, NFAT, NFkB, NRF2, P53, SMAD, SRF, and STAT3.
We treated human prostate fibroblast cells (P3158) with MnTE-2-PyP for 0, 4, 8, 16, 24,
and 48 hours to understand time dependent changes in the nuclear activity of the above
TFs. We observed that 48 hours of MnTE-2-PyP treatment causes an increase in activity
by ~1.5-fold or more in IRF, FOXO1, NFAT, NRF2, P53, HSF, SRF, STAT3, ATF4, NFkB
and SMAD (Fig. 31: A). This data indicates that MnTE-2-PyP treatment leads to activation
of other TFs at the 48-hour time point, which can be responsible for changes in some of
the transcriptional targets seen in the RNA-Seq data and radioprotection.
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Figure 31. Time dependent, MnTE-2-PyP mediated activation of 16 oxidative
stress related transcription factors. (A) Relative transcription factor activity of AP1,
ATF4, CBF/NFY, EGR1, ETS, FOXO1, HIF, HSF, IRF, NFAT, NFkB, NRF2, P53,
SMAD, SRF, and STAT3 over 0, 4, 8, 16, 24, and 48 hours of MnTE-2-PyP treatment
in nuclear extracts of P3158 cells.
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3.30.

Time dependent, radiation mediated activation of 16 oxidative stress related

transcription factors

We know that radiation exposure can lead to an increase in superoxide levels and other
ROS species. However, we are unsure of this increase in superoxide, and other ROS
species can activate oxidative stress sensitive transcription factors in prostate fibroblast
cells. To understand this process and better study the mechanisms of radioprotection, we
exposed human prostate fibroblast (P3158) cells to 3 Gy radiation and collected the
samples at 0, 1, 4, 8, 12, and 16 hours post-irradiation time points. Our results indicate, at
the 1 hour post-radiation time point, there was ~1.5-fold or more activation in IRF, NRF2,
STAT3 and ATF4 transcription factors (Fig. 32: B). NRF2 and SMAD activity also peaked
around the 12 hours post-radiation time point (Fig. 32: B). Further, the activity of TFs such
as FOXO1, HIF, CBF/NFY, HSF, SRF, STAT3, ATF4, NFkB, and SMAD show a decrease
in activity at the 8 hours post-radiation time point (Fig. 32: B). Overall, this data indicates
that radiation exposure does not lead to a substantial increase in the activity of oxidative
stress sensitive TFs but may lead to a decrease in the activity of TFs.
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Figure 32. Time dependent, radiation mediated activation of 16 oxidative stress
related transcription factors. (A) Relative transcription factor activity of AP1, ATF4,
CBF/NFY, EGR1, ETS, FOXO1, HIF, HSF, IRF, NFAT, NFkB, NRF2, P53, SMAD,
SRF, and STAT3 over 0, 1, 4, 8, 12, and 16 hours post-irradiation in nuclear extracts
of P3158 cells.
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3.31.

MnTE-2-PyP treatment and radiation exposure mediated changes in NQO1

mRNA in PC3 cells

Since activation of the NRF2 pathway by MnTE-2-PyP is involved in radioprotection in
normal human prostate fibroblast cells. We were investigated if MnTE-2-PyP activates
NRF2 signaling in prostate cancer cells. In PC3 (prostate cancer cell line) cells, MnTE-2PyP does not lead to a significant increase in NQO1 mRNA (Fig. 33: A), which is a NRF2
downstream target. Therefore, MnTE-2-PyP may not be involved in the radioprotection of
prostate cancer cells.
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Figure 33. MnTE-2-PyP treatment and radiation exposure mediated changes in
NQO1 mRNA in PC3 cells. (A) Relative NQO1 mRNA levels in PC3 cells. Differences
were determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for
multiple comparisons. The symbol (ns) denotes a non-significant difference as
compared to the control (PBS) group. Data were obtained from 3 independent
experiments, bars in the figures represent mean ± SEM.
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3.32.

MnTnBuOE-2-PyP (MnTE-2-PyP analog) also activates NRF2 signaling

MnTE-2-PyP’s analog molecule, MnTnBuOE-2-PyP (BuOE) is currently in clinical trials for
glioblastoma, head and neck cancer, and anal cancer as a radioprotector. MnTnBuOE-2PyP is a more lipophilic compound because of its extended alkyl chain and is used at a
much lower dose in comparison to MnTE-2-PyP to achieve radioprotection. Therefore, we
tested if MnTnBuOE-2-PyP can activate the NRF2 signaling pathway like MnTE-2-PyP at
a dose lower than 5 μM. Further, we tested if these compounds activate NRF2 signaling
in mouse myoblast cells C2C12 cells to understand its application in other tissue types for
other applications. Immunoblotting results showed an increase in NRF2 protein levels at
1.0 μM dose of MnTnBuOE-2-PyP treatment and 15 μM of MnTE-2-PyP treatment (Fig.
34: A-B). Similarly, a significant difference in expression of NQO1 was achieved at 1.0 μM
dose of MnTnBuOE-2-PyP treatment and 15 μM of MnTE-2-PyP treatment in C2C12 cell
line (Fig. 34: A). NOX4 showed a trend towards a decrease in expression, and SOD2
showed a trend towards an increase in expression with 1.0 μM dose of MnTnBuOE-2-PyP
treatment and 15 μM of MnTE-2-PyP treatment (Fig. 34: A). This indicates that both MnTE2-PyP and MnTnBuOE-2-PyP are activators of the NRF2 signaling pathway in different
cell types.
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Figure 34. MnTnBuOE-2-PyP (MnTE-2-PyP analog) also activates NRF2 signaling.
(A) Immunoblotting analysis of whole-cell lysate of C2C12 cells treated with
MnTnBuOE-2-PyP (BuOE) at 0.5 μM, 1.0 μM and MnTE-2-PyP at 15 μM for 96 hours.
(B) Quantification of NQO1 levels from immunoblot in panel A. Differences were
determined by using a 1-way ANOVA followed by a post hoc Tukey’s test for multiple
comparisons. The symbol (*p < 0.05, ***p < 0.0005) denotes a significant and the
symbol (ns) denotes a non-significant difference as compared to the control (PBS)
group. Data were obtained from 3 independent experiments, bars in the figures
represent mean ± SEM.
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Chapter 4.

4.1.

Conclusion and discussion

Significance of the NRF2 pathway activation in maintaining human health….

Several studies have reported that an active NRF2 pathway is involved in maintaining
human health and proper cellular functioning [254, 255]. NRF2 knockout mice are viable
and fertile, but show lower reproductive performance, reduced immobility, decreased
antioxidant reserve capacity and are extremely vulnerable to various toxic insults. This is
because NRF2 controls the expression of a battery of genes involved in various cellular
functions. The NRF2 pathway regulates oxidative stress, cellular metabolism, DNA repair,
drug transport, inflammation, and cross-talks with other signaling pathways.
The NRF2 pathway is the master regulator of oxidative stress in most cell types and is
involved in maintaining redox balance [209, 256]. It has been reported to control the
expression of all three SODs and other antioxidant proteins such as NQO1, glutathione stransferase (GST), catalase (CAT), thioredoxin (TRX), glutathione peroxidase (GPx), and
glutathione-disulfide reductase (GSR) through direct and indirect mechanisms. Levels of
superoxide and hydrogen peroxide are noticeably decreased upon the expression of the
NRF2 downstream targets. Superoxide generated by radiation exposure is one of the main
drivers for the development of RIF because studies involving the addition of SOD proteins
and SOD mimics protect from radiation damage. Mice treated with SOD1 show a decrease
in radiation-induced intestinal inflammation and upregulation of intercellular adhesion
molecule-1 (ICAM-1), which is involved in pro-inflammatory signaling [257]. SOD2
overexpression protects fibroblast cells from transformation induced by radiation [258260]. Similarly, SOD3 overexpression prevents an increase in the activation of the TGFβ1 signaling pathway, post-irradiation [261].
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In addition to superoxide removal through the downstream targets of the NRF2 pathway,
there are metabolic processes that contribute towards radioprotection. The NRF2
signaling pathway is directly involved in regulating drug metabolism, DNA repair, purine
metabolism, pentose metabolism, lipid metabolism, inflammation, and proteostasis.
NRF2 metabolic processes are regulated through the >242 NRF2 downstream
transcriptional targets that contain NRF2 binding sites and through the protein-protein
interactions of NRF2 [210, 262]. The NRF2 metabolic network inhibits lipogenesis,
supports beta-oxidation of fatty acids, facilitates flux through the pentose phosphate
pathway, increases NADPH regeneration and purine biosynthesis, which are essential
processes for replacing damaged macromolecules after radiation exposure. The NRF2
pathway impacts cellular bioenergetics by regulating the availability of mitochondrial
substrates required for respiration [263]. Absence of NRF2, lowers mitochondrial NADH
levels and ATP production due to inhibition of oxidative phosphorylation [263, 264]. To
compensate for a decrease in ATP production in NRF2 knockout cells, cells activate
glycolytic pathways. This highlights the importance of NRF2 in mitochondrial metabolism
and functioning [263]. Further, NRF2 regulates DNA repair by controlling the expression
of the enzyme 8-oxoguanine DNA glycosylase, which is involved in DNA base excision
repair [265, 266]. The NRF2 pathway is also involved in DNA double strand break repair
through its interaction with BRCA1 and regulation of 53BP1 expression [267].
In addition to radioprotection, the NRF2 pathway plays a significant role in the influx-efflux
of drugs and the metabolism of drugs. This regulation is carried out by several transporters
and metabolic enzymes that are downstream targets of the NRF2 pathway [268, 269]. We
also envision that when used in combination with toxic chemotherapy drugs, manganese
porphyrin compounds may help in the reduction of the chemotherapy toxicities due to
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activation of the NRF2 pathway in normal tissues, which will be discussed in future
directions.
As mentioned in the introduction, the NRF2 pathway crosstalks with the TGF-β signaling
pathway, which is the most widely reported pro-fibrotic pathway [226, 227, 270]. The
crosstalk between the NRF2 pathway and TGF-β pathway is responsible for the
expression of the fibrotic markers and ECM proteins, which can also lead to epithelialmesenchymal transitions and the formation of myofibroblast cells [271].
Inflammation plays a major role in the formation of myofibroblasts and the development of
RIF. The NRF2 pathway is known to crosstalk with the NF-κB pathway, which is a proinflammatory pathway [272]. NRF2 deficiency has been reported to increase NF-κB
activity, increase macrophage and neutrophil infiltration, increase serum levels of proinflammatory cytokines such as interleukin 6 (IL6), C-C Motif Chemokine Ligand 2 (CCL2),
interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin 12B (IL
12B), which contribute to radiation-induced injury [270, 272, 273]. NRF2 deficiency results
in an increase in ROS levels, which induce NFKB inhibitor alpha (IκBα) phosphorylation
and subsequent degradation, which leads to the activation of the NF-κB pathway [274].
Further, heme oxygenase 1 (HMOX1 or HO-1), a downstream target of the NRF2 pathway
can also inhibit the NF-κB pathway [272, 275, 276]. Conversely, activation of the NF-κB
pathway can inhibit the NRF2 pathway by depriving the CREB binding protein (CREBBP)
of the NRF2 transcription site and facilitating the recruitment of histone deacetylase 3
(HDAC3) [275, 277].
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4.2.

Mechanism

of

NRF2 pathway activation by manganese porphyrin

compounds

There are several mechanisms through which the NRF2 signaling pathway can be
activated. Our findings indicate that MnTE-2-PyP is a post-translational activator of the
NRF2 signaling pathway as we observed no change in NRF2 mRNA levels but did observe
a significant increase in NRF2 protein levels. Since manganese porphyrin compounds
convert superoxide to hydrogen peroxide, and the removal of hydrogen peroxide through
NAC treatment prevents NRF2 pathway activation in prostate fibroblast cells, we suspect
that hydrogen peroxide is causing NRF2 pathway activation through post-translational
modifications. In a recent study, an imbalance in superoxide-hydrogen peroxide levels
caused by paraquat (increases superoxide) and porphyrin exposure (SOD2-like molecule)
has been reported to be involved in NRF2 activation in keratinocytes [278]. Further,
MnTBAP, a SOD mimetic, has been reported to be an NRF2 activator in ratcardiomyoblasts [279]. Therefore, MnTE-2-PyP can activate the NRF2 pathway due to the
conversion of superoxide to hydrogen peroxide.
KEAP1 is a well-known inhibitor of NRF2 signaling that maintains homeostatic levels of
NRF2. KEAP1 binds DLG and ETH motifs of NRF2, which favors CUL3-mediated
ubiquitination of NRF2 and subsequent proteasome degradation [280, 281]. Hydrogen
peroxide, which is generated by manganese porphyrin compounds [168], is known to
cause oxidative modification and/or S-glutathionylation (in the presence of glutathione) of
cysteine residues of redox-sensitive proteins [167, 168, 177, 185, 206, 282, 283]. We have
shown that hydrogen peroxide levels increase 6 hours after MnTE-2-PyP treatment and
KEAP1 levels decrease around the 6 hour time point in prostate fibroblast cells. Therefore,
MnTE-2-PyP likely activates the NRF2 pathway due to oxidative modifications or posttranslational modifications of KEAP1 due to hydrogen peroxide generation.
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Alternative mechanisms of NRF2 pathway activation by manganese porphyrin compounds
could involve changes in NRF2 phosphorylation at Ser-40 by protein kinase C (PKC),
mitogen-activated protein kinase 14 (MAPK14 or p38), extracellular-signal-regulated
kinase (ERK), PI3K/AKT, and changes in ubiquitination/proteasomal degradation [212,
284, 285]. An increase in NRF2 phosphorylation by glycogen synthase kinase 3 beta
(GSK3B) can decrease its nuclear accumulation [286]. Further, NRF2 cysteine residues
(Cys235, Cys311, Cys316, Cys414, and Cys506) can undergo electrophilic modification or posttranslational modifications similar to those seen on KEAP1 [287]. To further understand
these mechanisms of NRF2 pathway activation, we plan to perform mass spectrometry
experiments

after

MnTE-2-PyP

treatment

and

measure

the

post-translational

modifications of the NRF2 pathway proteins.

4.3.

The mechanism by which MnTE-2-PyP prevents myofibroblast formation

Radiation-induced fibrosis (RIF) is caused by the transformation of fibroblasts to
myofibroblasts. This transformation of fibroblasts is driven by ROS generated after
radiation exposure [6]. Superoxide levels increase immediately after radiation exposure
and native SOD enzymes convert some of this superoxide to hydrogen peroxide.
However, this is not enough to prevent fibroblast transformation. The addition of MnTE-2PyP boosts the cellular capacity to convert superoxide to hydrogen peroxide through direct
and indirect mechanisms, which is sufficient to prevent the development of RIF. However,
we do not completely understand the mechanism of KEAP1 oxidation or other
modifications caused by the hydrogen peroxide generated by manganese porphyrin
compounds. Further, the location of the hydrogen peroxide generated by manganese
porphyrin compounds may differ from that of SOD enzymes.
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Two essential NRF2 downstream targets involved in cellular protection against radiation
exposure are NQO1 and SOD2. NQO1 serves as a cytoprotective and metabolic protein
that generates NAD+, which serves as a cofactor to increase the activity of the sirtuin family
of proteins [239, 240, 288]. We have confirmed an increase in cellular NAD+ levels and an
increase in sirtuin activity within nuclear and mitochondrial extracts. In addition to the
increase in SOD2 expression caused by NRF2 pathway activation, mitochondrial sirtuin
proteins can deacetylate SOD2 to increase its enzymatic activity and further enhance
mitochondrial superoxide scavenging capacity, likely due to an increase in NAD+ levels.
This could lead to a long-term increase in superoxide scavenging capacity and improved
mitochondrial health due to manganese porphyrin treatment.
The inner mitochondrial membrane is impermeable to NADH and NAD+. However, the
electrons from NADH can be carried by either the glycerol 3-phosphate shuttle or the
malate-aspartate shuttle to regenerate the NADH within the mitochondria [289-291]. We
acknowledge that the changes in NAD+ levels after MnTE-2-PyP treatment and the NRF2
pathway activation may be independent of changes in NQO1 levels. They could be
associated directly with changes in mitochondrial health, number, and activity, or other
NRF2 downstream targets [292, 293]. However, the role of NAD+ in increasing sirtuin
activity and cellular protection is well known [237, 240, 241, 288, 294-296].
NAD+ precursor nicotinamide, has been shown to prevent endothelial-to-mesenchymal
transition induced by TGF-β [297] and renal fibrosis by suppressing inflammation [298].
Further, targeting NAD+ metabolism in cancer enhances its radiosensitivity [299].
The increase in activity of sirtuin proteins has been shown to be involved in radioprotection
through the use of compounds such as resveratrol [300] and polydatin [132]. Sirtuin
proteins are also known to exert antifibrotic effects [301], delay aging, and regulate
metabolic processes that protect mice from diet-induced obesity, type 2 diabetes, and
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nonalcoholic fatty liver disease [244]. We have previously reviewed the role of each of the
sirtuin proteins and their targets in RIF [39]. However, we still need to investigate the
acetylation status of targets other than SOD2 that could play a role in the prevention of
RIF after MnTE-2-PyP treatment.
Through knockdown experiments of NRF2, we confirmed that NRF2 is essential to prevent
prostate fibroblast to myofibroblast transformation, and MnTE-2-PyP fails to prevent this
transformation in the absence of NRF2 upon irradiation. Further, the NRF2 pathway is
also known to inhibit the TGF-β signaling pathway, a known pro-fibrotic pathway that
controls the expression of several extracellular matrix proteins and α-SMA expression,
which has been discussed in the previous section [226, 227]. Previously, our laboratory
has confirmed that MnTE-2-PyP inhibits TGF-β1-mediated fibroblast activation and
expression of fibrotic markers (Fig. 35) [1].
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Figure 35. The mechanism by which MnTE-2-PyP prevents
myofibroblast formation. Exposure to radiation generates superoxide
in fibroblasts leading to transformation to myofibroblasts. MnTE-2-PyP
treatment coverts this superoxide to hydrogen peroxide, which can
oxidize redox sensitive proteins. KEAP1 is a redox sensitive protein that
can be oxidized by hydrogen peroxide. Oxidized KEAP1 dissociates from
NRF2 (inactive state) in the cytoplasm and can lead to a reduction in
KEAP1 levels. NRF2 upon dissociation (active state) translocates to the
nucleus to bind ARE elements in the promoter region of genes such as
NQO1 and SOD2. An increase in NQO1 causes metabolic changes that
can lead to an increase in NAD+ that serve as a cofactor for the sirtuin
(SIRT) family of proteins. We have observed an increase in sirtuin activity
in the mitochondria that also correlates with deacetylation of SOD2
(K122) protein. An increase in SOD2 expression and deacetylation by
mitochondrial sirtuin proteins leads to enhancement in SOD2 activity,
further augmenting superoxide scavenging capacity upon MnTE-2-PyP
treatment. Therefore, we observe a significant decrease in superoxide
levels in fibroblast cells, which prevents its transformation to
myofibroblasts. Our laboratory has previously observed inhibition of the
TGF-β1/SMAD signaling pathway that is responsible for the α-SMA
expression by MnTE-2-PyP treatment [1]. Based on other studies, we
speculate that this occurs due to the crosstalk of the NRF2 signaling
pathway with the TGF-β1 signaling pathway.
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4.4.

Reduction of POSTN and COL3A1 in fibroblasts by MnTE-2-PyP

We have shown MnTE-2-PyP to downregulates periostin (POSTN), which is also known
as osteoblast-specific factor 2, in mouse and human prostate fibroblast cells. We suspect
MnTE-2-PyP downregulates POSTN expression due to NRF2 pathway activation as it has
been reported to be one of the downstream targets [225, 302, 303]. POSTN, is a
component of the ECM involved in regulating intercellular adhesion and plays a key role
during development and wound repair [304]. POSTN contributes to proper collagen
function and is predominantly expressed in collagen-rich tissues such as the skin [305].
High expression of POSTN correlates with the development of a fibrotic phenotype in
several tissues [302, 306-312]. It is known to promote myofibroblast formation and type 1
collagen production through TGF-β activation [310, 313-316]. The mechanism of POSTNinduced activation of TGF-β involves an increase in the activity of matrix metallopeptidase
2 (MMP2) and matrix metallopeptidase 9 (MMP9) [313]. Loss of POSTN ameliorates
adipose tissue fibrosis and inflammation due to a reduction in macrophage recruitment
[304, 317]. POSTN expression in fibrosis and inflammation is believed to be enhanced
due to the secretion of interleukin 4 (IL4) and interleukin 13 (IL13) cytokines [315]. Further,
POSTN is involved in progression of prostate [318-321], breast [322], lung [323], ovarian
cancer [324], and nasopharyngeal cancer [318, 325]. POSTN interacts with multiple cellsurface receptors, most notably integrins, and signals via the PI3K/AKT pathway to
promote tumor aggressiveness [309, 318]. Therefore, reduction in POSTN by MnTE-2PyP is an important finding that could play a role in prevention of RIF and prostate cancer
growth post-irradiation.
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COL3A1 is one of the matrisome proteins whose expression is also regulated by NRF2 in
fibroblasts [225, 326, 327]. We have observed that MnTE-2-PyP decreases COL3A1
expression from human and mice prostate fibroblasts. An increase in COL3A1 expression
correlates with the development of fibrosis and other fibrotic markers such as α-SMA,
COL1A1, and fibronectin [326, 328-330]. Mutations in COL3A1 is known to disrupt the
formation of ECM [328, 331]. An increase in oxidative stress results in impaired NEDD9
proteolytic degradation, thereby increasing the formation of the neural precursor cell
expressed, developmentally down-regulated 9 and NK2 Homeobox 5 (NEDD9-NKX2–5)
complex that increases COL3A1 expression [330]. Therefore, we think that the reduction
in oxidative stress by MnTE-2-PyP treatment or NRF2 pathway activation contributes
towards the reduction in COL3A1, which is a marker for fibrosis.

4.5.

Applications of manganese porphyrin compounds as NRF2 activators in

other disorders and diseases

We have shown manganese porphyrins work as NRF2 activators that helps in
radioprotection. Additionally, there are several other NRF2 activators that are either plantderived chemicals or synthetic chemicals that have demonstrated radioprotection and are
being used for other chronic diseases. However, manganese porphyrins are more
effective in activating the NRF2 pathway due to its catalytically active properties. We have
observed a dose dependent increase in NRF2 pathway activation, and we can control the
levels of NRF2 pathway activation by adapting the correct dosing strategies.
NRF2 activators that are plant-derived phytochemicals include sulforaphane, curcumin,
epigallocatechin-3-gallate, resveratrol, cafestol, kahweol, cinnamonyl-based compounds,
zerumbone, garlic oganosulfur compounds, lycopene, and carnosol [332]. Synthetic
chemicals developed in the laboratory include oltipraz (4-methyl-5-[2-pyrazinyl]-1,2-
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dithiole-3-thione) and dimethyl fumarate (DMF), which is also known as BG-12 or
Tecfidera (Oral formulation) [332]. Additionally, new NRF2 activator compounds such as
2-trifluoromethyl-2’-methoxychalone, mitigates myelosuppression and radiation damage
[333]. These compounds can be classified into different categories depending on the
mechanism of NRF2 pathway activation; electrophilic compounds, non-electrophilic
compounds or protein-protein interaction inhibitors, GSK-3 inhibitors, synoviolin 1 (SYVN1
or HRD1) inhibitors (LS-102), p62 (SQSTM1) activator (rapamycin), and BTB domain and
CNC homolog 1 (BACH1) inhibitor (HPP-4382) [334]. Electrophilic compounds that cause
electrophilic modification of KEAP1 cysteine residues and include molecules such as
bardoxolone-methyl, RTA-408, DMF, ALKS-8700, oltipraz, ursodiol, sulforaphane
ITH12674, curcumin, resveratrol, and CXA-10. Non-electrophilic compounds or proteinprotein interaction inhibitors, which interfere in NRF2-KEAP1 interaction, include peptides,
1,2,3,4-tetrahydroisoquinoline

core,

benzenesulfonyl-pyrimidone,

1,4-

diaminonaphthalene core, sulfonyl coumarins and arylcyclohexyl pyrazoles. GSK-3
inhibitors include tideglusib, nordihydroguaiaretic acid, terameprocol and enzastaurin
[334]. Based on our findings manganese porphyrin compounds likely belong to the
category of electrophilic compounds that cause NRF2 activation through KEAP1
modification.
NRF2 activator drugs are under clinical development for a plethora of chronic disorders
and diseases that require restoring of redox balance, resolution of inflammation, and
normalizing mitochondrial metabolism [211, 281, 334]. NRF2 activators also function as
chemopreventive and chemoprotective molecules. Conversely, NRF2 inhibitor drugs have
demonstrated to have anticancer properties for tumors that have a hyperactive NRF2
pathway [334]. To date, the most successful NRF2 activator is fumaric acid ester dimethyl
fumarate (DMF, BG-12 or Tecfidera, from Biogen) that has been approved by the FDA in
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2013 for multiple sclerosis [335]. Other NRF2 activator drugs are currently in different
phases of clinical trials for their application in diabetes, kidney disease, liver disease,
lymphoid malignancies, Alport syndrome, pulmonary hypertension, mitochondrial
myopathy, Friedreich’s ataxia, inflammation, cancer, psoriasis, rheumatoid arthritis,
schistosomiasis, nonalcoholic steatohepatitis, nonalcoholic fatty liver, chronic hepatitis C,
cholelithiasis, diarrhea and pulmonary arterial hypertension [211].
Drugs such as resveratrol have been shown to decrease KEAP1 levels and activate NRF2
signaling, similar to MnTE-2-PyP [336, 337]. Resveratrol has been used as a
radioprotector in several publications for tissues other than the prostate (intestine, salivary
gland, ovary, hematopoietic stem cells, skin, and lung) [135, 136, 139, 140, 338]. Further,
resveratrol has also been shown to be an activator of sirtuin proteins [336]. Like MnTE-2PyP, resveratrol has been shown to scavenge superoxide molecules, directly and
indirectly, however, the clinical application of resveratrol has been unsuccessful due to
poor oral bioavailability (less than 5%), as it undergoes rapid metabolism and elimination
[339, 340]. Resveratrol is not a catalytically active compound whereas, manganese
porphyrin compounds are catalytically active and hence do not require high dose of
treatment. The bioavailability of MnTE-2-PyP has been studied in different tissues [167],
and its bioavailability can be enhanced by up to 120-fold by changing the alkyl chain, which
modulates its lipophilicity [341]. Therefore, MnTE-2-PyP, as a superoxide scavenger,
NRF2 activator, SOD2, and NQO1 enhancer, and a sirtuin activator would work as a
superior radioprotector and would be applicable for other chronic disease involving
oxidative stress.
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4.6.

Mechanisms associated with antitumor and radiosensitizing effects of

manganese porphyrin compounds

Manganese porphyrin compounds have demonstrated antitumor and radiosensitizing
effects in prostate cancer and other cancers [342, 343]. This is mainly due to the
differences in cellular networks and oxidative stress levels that are present between tumor
and normal tissues. Manganese porphyrin compounds work as a prooxidant in some
cancers and as an antioxidant in normal tissues post-radiation due to the differences in
the intracellular microenvironment. The relative oxidative stress levels in normal tissue are
much lower in comparison to the cancer cells of certain cancer types. Further, we think
that the activity and expression of antioxidant enzymes have been maximized in certain
cancers and, therefore, are more susceptible to cell death by the prooxidant effects of
manganese porphyrin compounds.
In prostate cancer, specifically in the PC3 cancer cell line, manganese porphyrins produce
high levels of intracellular hydrogen peroxide (up to a 2-fold increase in the nucleus) [234].
This leads to oxidation of a chromatin-modifying protein, P300, which is a histone
acetyltransferase (HAT) enzyme. This results in a decrease in affinity for P300
transcriptional complex to the DNA and a change in the transcriptional profile of cancer
cells. Further, a reduction in histone acetylation (H3K9Ac) at specific gene promoters (PAI1) can be observed. However, we have not observed an activation of the NRF2 pathway
in the PC3 cell line. We think that the NRF2 pathway in these cancer cells (PC3) might be
defective, thereby preventing its activation and increasing its susceptibility to radiation
damage. Further, the level of hydrogen peroxide increase in these cells might be triggering
cell death pathways and causing DNA damage before any activation of the NRF2
pathway. Therefore, additional changes in the oxidation of other proteins due to hydrogen
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peroxide generation by manganese porphyrin in prostate cancer cells and normal
fibroblast cell is under investigation in our laboratory.
Understanding the differential pathways and molecules in normal tissues versus prostate
cancer altered by manganese porphyrin compounds will vastly improve the therapeutic
application of manganese porphyrin compounds and is the biggest challenge in the field.
The ability of native antioxidant enzymes that can scavenge hydrogen peroxide generated
by manganese porphyrin compounds determines their role as radioprotective agents or
radiation sensitizing agents. In our laboratory, we are investigating the oxidation of some
of the proteins in prostate cancer, which would further explain the mechanism of antitumor
and radiosensitizing effects of manganese porphyrin compounds.

4.7.

Future directions

We have shown that MnTE-2-PyP protects from radiation-induced myofibroblast formation
through the activation of NRF2 signaling by knockdown experiments. However, radiation
had no effect on the activation of NRF2-/- primary mice prostate fibroblast cells ex vivo. It
is possible that these prostate fibroblast cells isolated from NRF2-/- mice already have a
myofibroblast phenotype due the stress of handling the cells that prevents its activation
post-irradiation. We also observed that these NRF2-/- prostate fibroblast cells are more
difficult to culture in vitro and do not proliferate as well as the wild-type prostate fibroblast
cell. It is possible that they might be more senescent and thereby preventing their
activation post-irradiation. It has been shown that the intestinal crypts of NRF2-/- mice are
radiation-resistant [223]. Therefore, for future studies the best model to study the role of
NRF2 in radioprotection of the prostate after MnTE-2-PyP treatment would be to develop
a NRF2 specific prostate conditional knockdown or overexpression system.
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We are currently investigating radioprotection mediated by the NRF2 pathway using wildtype and NRF2-/- mice, exposed to radiation ± MnTE-2-PyP. We have begun scoring for
the visible symptoms of radiation damage after pelvic radiation exposure. Mice were
exposed to a total of 35 Gy, which was fractionated over five days at 7 Gy each day. We
evaluated radiation damage every week and scored the mice for hair loss, sores, tucked
leg, redness or inflammation, and a prolapsed penis (Appendix A, Fig. 36). This ongoing
experiment will be continued for a total of 4 months to measure changes in chronic
radiation-induced damage. At the end of 4 months, different pelvic tissues (Prostate,
colon, bladder, and skin) will be collected to investigate the formation of myofibroblasts
and fibrosis. We suspect that the NRF2-/- mice may show a more severe fibrotic phenotype
upon radiation exposure in comparison to the wild-type mice. This experiment would also
help us determine the role of manganese porphyrin compounds in preventing
myofibroblast formation in vivo due to direct ROS scavenging.
For our future studies, we would also like to explore the growth of prostate cancer in NRF2/-

mice versus wild-type mice. The results of this experiment would determine if the

activation of NRF2 by MnTE-2-PyP in normal tissue would have an impact on prostate
cancer growth. Alternatively, we can isolate prostate fibroblast cells from NRF2-/- mice and
wild-type mice and co-culture these fibroblast cells with prostate cancer cells and assess
the proliferation of cancer cells.
In vivo studies of the development of RIF in the presence of tumor cells still need to be
performed. Tumor cells develop a microenvironment that is different from that seen in
normal tissues without tumor. The fibroblast cells associated with the cancer are referred
to as cancer-associated fibroblasts (CAFs). CAFs have a phenotype that is different from
the normal fibroblasts. Their phenotype resembles more of an activated fibroblast or
myofibroblast. Their secretory profile is different from the normal fibroblasts, and we think
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that understanding changes in CAFs upon radiation exposure ± MnTE-2-PyP treatment
and its impact on the tumor cells would be one of the future directions of the project. We
think that MnTE-2-PyP treatment may inhibit some of the secretory molecules from the
CAFs, such as POSTN, which would impact prostate tumor growth.
We have confirmed NRF2 pathway activation by manganese porphyrin compounds in
different cell lines in our in vitro experiments. However, we still need to confirm NRF2
pathway activation in mice treated with the drug. Preliminary results of mice treated with
MnTE-2-PyP show a likely activation of the NRF2 pathway after two months of treatment
in wild-type C57BL/6J mice obtained from The Jackson Laboratory (Appendix B, Fig. 37).
In prostate and liver tissue, we see a trend towards the upregulation of NQO1 mRNA. A
similar trend was observed in NQO1 protein levels in skin and liver tissues by
immunoblotting. Bladder and colon tissue do not show a trend in the upregulation of NQO1
mRNA. We suspect that only certain cell types, such as fibroblast cells, might have an
activation of the NRF2 pathway upon MnTE-2-PyP treatment in some of these tissues.
The heterogeneous tissue lysate samples analyzed might not be the best indicator for
NRF2 pathway activation by MnTE-2-PyP treatment in vivo. Further, our results may be
significant only if we examine the different cell types in these tissues separately. In an
acute, 2 week experiment of PBS and MnTE-2-PyP treatment, of wild-type C57BL/6J mice
obtained from the Charles River Laboratory, we did not see a trend towards an increase
in NRF2, NQO1 or SOD2 protein levels in kidney, liver, prostate and skin tissue of mice
(Appendix C, Fig. 38). We did observe a trend in the increase in NRF2 levels in kidney
and liver tissue, but this change in NRF2 levels did not translate to a corresponding rise
in NQO1 or SOD2 levels. To further test the activation of the NRF2 pathway in vivo in
different tissue types, we can use the transgenic NRF2-luciferase (NRF2-luc) reporter
mice and perform real-time bioluminescence imaging upon MnTE-2-PyP or PBS treatment
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[344]. This would help us determine the time taken for activation of the NRF2 pathway in
different tissue types and determine the frequency of MnTE-2-PyP treatment required to
maintain high NRF2 pathway activity. Alternatively, transgenic mice expressing human
placental alkaline phosphatase (hPAP) under control of the rat NQO1 ARE and a minimal
promoter (ARE-hPAP reporter mice), can be used for visualization of cells featuring the
NRF2 pathway activation upon MnTE-2-PyP treatment [345].
We know that KEAP1 is a vital redox sensor and is subjected to several different kinds of
post-translational modifications [346, 347]. Modification of the sulfhydryl groups (cysteine
residues) in KEAP1 can lead to the dissociation of NRF2 from KEAP1 [346, 347]. KEAP1
has 27 and 25 cysteine residues in human and mouse protein, respectively [346]. Analysis
of cysteine modifications of KEAP1 at C257, C226, C613, C622, C624, C272, C288, and C297
through mass spectrometry experiments would be the next step to understand the
mechanisms of NRF2 pathway activation by manganese porphyrin compounds [346].
KEAP1 uses C226, C613, C622, and C624 residues to sense H2O2 [346]. H2O2 is a critical ROS
molecule that plays an essential role in cellular physiology at low levels and has been
associated with multiple human diseases at higher concentrations. H2O2 can oxidize
cysteine residues to form intra- or inter-molecular disulfide bonds between two cysteine
residues, thereby modulating the function and stability of several proteins, including
KEAP1.
The use of NRF2 inhibitors to treat different cancers might increase the damage caused
to normal tissues during radiation therapy. Further, they might cause the development of
fibrotic tissues or the transformation of fibroblasts to myofibroblasts, even in the absence
of radiation exposure. Hence, the use of NRF2 inhibitors such as brusatol, ascorbic acid,
luteolin, ochratoxin A, trigonelline, and all-trans retinoic acid could have severe toxicity
concerns over a more extended period [332]. However, they serve as an essential tool for
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in vitro experiments and would help in determining the role of NRF2 pathway activation by
manganese porphyrin compounds in different diseases. Along with the use of NRF2
inhibitors to test the various hypotheses, we can also use inhibitors of the downstream
targets of the NRF2 pathway, such as dicoumarol, which is an inhibitor of NQO1 activity.
Alternatively, we can test the significance of the NRF2 pathway activation in
radioprotection using NRF2 activators (discussed in the previous section) that are different
from manganese porphyrin compounds. To examine the role of NRF2 downstream targets
in radioprotection, we would like to generate an inducible knockdown system of NQO1
and SOD2 in prostate fibroblast cells. We would then test for changes in the myofibroblast
markers and the myofibroblast phenotype, post-irradiation ± MnTE-2-PyP treatment. We
would further verify the changes in NAD+ and NADH levels in the absence of NQO1.
Understanding the metabolic network and the impact on the activity of sirtuin proteins will
help determine novel radioprotective mechanisms in fibroblasts.
We have identified the upregulation of SOD2 protein upon manganese porphyrin
treatment. However, we have not confirmed if this is a transcriptional upregulation of
SOD2 due to the NRF2 pathway activation. SOD2 expression is regulated by a host of
different transcription factors, including NRF2. Further, SOD2 protein upregulation was
observed before a significant increase in NRF2 pathway activation (Fig. 9) and in KEAP1
knockout MEFs (Fig. 16). Therefore, NRF2 pathway activation by MnTE-2-PyP treatment
may only be partially responsible for SOD2 upregulation. Further analysis of changes in
activity of transcription factors such as specificity protein 1 (SP1), activating enhancerbinding protein 2 (AP2), tumor protein p53 (p53), forkhead box o3 (FOXO3A), NF-κB,
hypoxia-inducible factor 1 (HIF-1), and cAMP response element-binding protein (CREB)
may help determine the regulation of SOD2 expression by manganese porphyrin

164
compounds, which would further improve our understanding of antioxidant properties of
manganese porphyrin compounds.
The use of manganese porphyrin compounds in chemoprotection is a new area of
research that we think can have a significant clinical impact. The activation of the NRF2
pathway by manganese porphyrin compounds would help protect normal tissue from the
toxicities of chemotherapy. In this view, we plan to investigate the role of manganese
porphyrin compounds in preventing toxicity caused by Gemcitabine or FOLFIRINOX, on
blood cells. In muscle cells, manganese porphyrin compounds would alter the metabolic
network through NRF2 pathway activation and prevent the formation of the cachectic
phenotype seen in pancreatic cancer patients. A potential problem with this strategy is
that it may reduce the anticancer activity of chemotherapy drugs. However, most
pancreatic cancer tumors have a hyperactivated NRF2 signaling pathway, and the
addition of manganese porphyrin compounds may not enhance its drug metabolism
potential.
Overall, we have observed that manganese porphyrin compounds are effective
radioprotectors and prevent the formation of the myofibroblast cells post-irradiation. There
are several molecular pathways altered by manganese porphyrin compounds, and one of
the essential pathways activated by manganese porphyrin compounds is the NRF2
pathway. The NRF2 pathway is a radioprotective pathway that reduces the overall
oxidative stress and controls other major cellular functions that are responsible for cellular
protection through the downstream targets. Identification of this molecular insight in the
role of manganese porphyrin compounds has clinical implications in radioprotection and
the application of these compounds in other diseases, which is being further explored in
our laboratory.
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Appendix.

Appendix A: Role of NRF2 pathway activation by MnTE-2-PyP in radioprotection.
To confirm the role of NRF2 pathway mediated radioprotection in MnTE-2-PyP treated
mice, we utilized C57BL/6J mice (wild type) and C57BL/6J Nfe2l2tm1Ywk (NRF2)
knockout mice and exposed them to pelvic radiation with or without MnTE-2-PyP
treatment.
Materials and methods: C57BL/6J mice (wild type) and C57BL/6J Nfe2l2tm1Ywk (NRF2)
knockout mice were exposed to a total of 35 Gy, which was fractionated over 5 days at 7
Gy each day. Mice received 5 mg/kg of MnTE-2-PyP or PBS one day before radiation
exposure as the loading dose. During the week of radiation and the following 2 weeks,
mice received 2.5 mg/kg of MnTE-2-PyP three times a week. For the remaining time,
mice received 5 mg/kg of MnTE-2-PyP once every week. Mice were scored for radiation
damage every week by giving one point for each of the following symptoms, hair loss,
sores, tucked leg, redness or inflammation and a prolapsed penis. Radiation damage
was monitored for a total of two months since the start of the experiment.
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Figure 36. Role of NRF2 pathway activation by MnTE-2-PyP in radioprotection.
Wild-type and NRF2-/- mice were exposed to a total of 35 Gy, which was fractionated
over 5 days at 7 Gy each day. We observed for radiation damage every week and
scored the mice for hair loss, sores, tucked leg, redness or inflammation and a
prolapsed penis (n = 6-8 mice/group).
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Appendix B: NRF2 pathway activation, in mice treated with MnTE-2-PyP for two
months.
Materials and methods: To confirm the activation of the NRF2 pathway in vivo, we isolated
prostate, bladder, liver, colon and skin tissue from C57BL/6J wild-type mice obtained from
The Jackson Laboratory treated with MnTE-2-PyP for two months. Mice were treated with
PBS or MnTE-2-PyP (5 mg/kg) three times for the first 2 weeks and then once a week for
the remaining time. Tissue samples were frozen immediately after isolation at -80 °C.
Tissue samples were homogenized using a Dounce Homogenizer in lysis buffer. Cell
lysates were made from the tissue samples using whole tissue lysis buffer for
immunoblotting experiments and NRF2 pathway activation was looked at my looking at
changes in NQO1 protein. For RNA isolation, RNA lysis buffer from ZR RNA MicroPrep
RNA isolation kit (R1065, Zymo Research) according to the manufacturer’s protocol. We
measured changes in NQO1 mRNA using mouse NQO1 RT-qPCR primers mentioned in
Table 2.
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Figure 37. NRF2 pathway activation, in mice treated with MnTE-2-PyP for two
months. Wild-type C57BL/6J mice obtained from the Jackson Laboratory, were treated
with PBS or MnTE-2-PyP for two months. Mice were treated with PBS or MnTE-2-PyP
(5 mg/kg) three times for the first 2 weeks and then once a week for the remaining time.
Prostate, bladder, colon, liver and skin tissue were isolated and stored at -80 °C before
analysis for NRF2 pathway activation. (A) Relative NQO1 mRNA levels in prostate
tissues. (B) Relative NQO1 mRNA levels in bladder tissues. (C) Relative NQO1 mRNA
levels in colon tissues. (D) Relative NQO1 mRNA levels in liver tissues. (E) Relative
NQO1 protein levels in skin tissues. (F) Relative NQO1 protein levels in liver tissues,
(n = 3 mice/group).
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Appendix C: NRF2 pathway activation, in mice treated with MnTE-2-PyP for two
weeks.
Materials and methods: To confirm the activation of the NRF2 pathway in vivo, we isolated
kidney, liver, prostate and skin tissue from wild-type C57BL/6J mice obtained from the
Charles River Laboratories, that were treated with PBS or MnTE-2-PyP for two weeks.
Mice were treated with PBS or MnTE-2-PyP (5 mg/kg) once every two days for two weeks.
before analysis for NRF2 pathway activation. Tissue samples were frozen immediately
after isolation at -80 °C. Tissue samples were homogenized using a Dounce Homogenizer
in lysis buffer. Cell lysates were made from the tissue samples using whole tissue lysis
buffer for immunoblotting experiments and NRF2 pathway activation was looked at my
looking at changes in NRF2, NQO1 and SOD2 protein levels.
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Figure 38. NRF2 pathway activation, in mice treated with MnTE-2-PyP for two
weeks. Wild-type C57BL/6J mice obtained from the Charles River Laboratories, were
treated with PBS or MnTE-2-PyP for two weeks. Mice were treated with PBS or MnTE2-PyP (5 mg/kg) once every two days for two weeks. Kidney, liver, prostate and skin
tissue were isolated and stored at -80 °C before analysis for NRF2 pathway activation.
(A) Relative NRF2, NQO1 and SOD2 levels in kidney tissues. (B) Relative NRF2,
NQO1 and SOD2 levels in liver tissues. (C) Relative NRF2, NQO1 and SOD2 levels in
prostate tissues. (D) Relative NRF2, NQO1 and SOD2 levels in skin tissues, (n = 5
mice/group).
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